SEARCH
Search Details
OHJI GoResearch Center for Urban Safety and SecurityAssociate Professor
Research activity information
■ Award■ Paper
- Apr. 2025, Diagnostics[Refereed]Scientific journal
- OBJECTIVE: This study aimed to evaluate the association between viral-load (VL)-suppression status and treatment satisfaction, depression, anxiety, and treatment needs in people living with HIV (PLWH). METHODS: A multicenter, cross-sectional study was conducted from April to December 2021. Eligible patients were classified into two groups based on their VL in the year prior to answering the questionnaires: those with all VL < 50 copies/mL (complete-VL-suppression group) and those with at least one VL ≥ 50 copies/mL (incomplete-VL-suppression group). The HIV Treatment Satisfaction Questionnaire: Status (HIVTSQs), the Patient Health Questionnaire-9 (PHQ-9), the Generalized Anxiety Disorder-7 (GAD-7), and the drug formulation needs were compared between the two groups. RESULTS: Of the 534 patients included in the analysis, 467 and 67 were classified into the complete and incomplete-VL-suppression groups, respectively. The total HIVTSQs scores (median [interquartile range (IQR)]) were 59.0 [53.0-64.0] and 56.0 [52.0-62.5] in the complete and incomplete-VL-suppression groups, respectively, with no significant difference. The incomplete-VL-suppression group scored significantly lower on the individual question for HIV control than the complete-VL-suppression group (5.0 [5.0-6.0] vs. 6.0 [5.0-6.0], P = 0.001). The total PHQ-9 and GAD-7 scores were not significantly different between the groups. The proportion of patients who preferred the once-every-month subcutaneous formulation was higher in the incomplete-VL-suppression group compared to the complete-VL-suppression group (16.4 % vs. 7.5 %, P = 0.028). CONCLUSIONS: The association between VL-suppression status and overall treatment satisfaction, depression, or anxiety was not detected. However, satisfaction with HIV control and treatment needs may differ in PLWH with incomplete VL-suppression.Apr. 2025, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 31(6) (6), 102711 - 102711, English, International magazine[Refereed]Scientific journal
- BACKGROUND: Approximately 7% to 29% of cardiac implantable electrical device (CIED) infection patients have unknown causative organisms using normal culture methods. An "enrichment culture" is an effective technique for identifying slow-growing, low-abundance, and fastidious microorganisms. OBJECTIVE: This study aimed to explore the causative organisms of CIED infections using enrichment cultures and to examine their relationship with the infection onset timing. METHODS: A total of 117 patients with CIED infections were analyzed. We categorized the onset timing of the CIED infections as the "early group" (n = 45) within 365 days of the last device procedure and the "late group" (n = 72) thereafter. RESULTS: Using the enrichment culture method, the causative microorganisms were identified in 97% of cases with CIED infections. The Staphylococcus species accounted for most (63%) infections. However, Cutibacterium acnes was notably high at 18%, surpassing prior findings. Patients who experienced early infections exhibited characteristics of having more pocket infections, fewer male patients, a lower left ventricular ejection fraction, higher brain natriuretic peptide level, and lower renal function. Furthermore, late infections exhibited a significantly higher frequency of Cutibacterium acnes (24% vs 8%; P = .02), and lower frequency of Staphylococcus aureus than early infections (25% vs 43%; P = .04). Enrichment cultures demonstrated a significantly higher detection rate of causative organisms than conventional blood agar cultures, regardless of the bacterial species. CONCLUSION: Utilization of enrichment cultures could highlight a disparity in pathogen distribution compared with previous reports. Cutibacterium acnes played a particularly significant role as the causative pathogen in the late onset of CIED infections.Apr. 2025, Heart rhythm, English, International magazine[Refereed]Scientific journal
- Introduction. Timely and accurate diagnosis of bacterial infections enables early administration of appropriate antimicrobial treatment and improved outcomes.Hypothesis/Gap Statement. The accuracy of computer-aided diagnosis (CAD) for identifying organisms on urine Gram stains has not been compared with that of microbiology specialists (MS).Aim. To compare the interpretation of urine Gram-stain results by MS and a CAD app designed using artificial intelligence.Methodology. Urine specimens from patients with urinary tract infections were used and collected at two tertiary hospitals between 1 April and 31 December 2022. Using non-inferiority analysis to assess whether CAD was non-inferior to expert interpretation, CAD-predicted microscopic findings of the Gram-stained slide generated from iPhone camera images from two hospitals were compared with those from ten MS. A total of 153 images were taken from each hospital, and CAD interpreted a total of 306. The primary endpoint was the prediction accuracy based on the morphology of the Gram-stained bacteria.Results. The accuracy (95% confidence interval) of MS and CAD predictions was 83.0% (81.6%-84.3%) and 87.9% (83.7%-91.3%), respectively, with a difference of -4.93% (-8.43% to -0.62%) indicating non-inferiority of CAD.Conclusion. CAD was non-inferior to MS predictions for identifying Gram-stained pathogens; therefore, CAD was suggested to have the potential for guiding empirical antibiotic selection in patients with urinary tract infections.Apr. 2025, Journal of medical microbiology, 74(4) (4), English, International magazine[Refereed]Scientific journal
- We retrospectively reviewed patients with Corynebacterium striatum bacteremia treated with daptomycin. All 11 isolates were initially susceptible to daptomycin, but the emergence of daptomycin nonsusceptibility during treatment and clinical failure occurred in 36% and 45% of patients, respectively.Nov. 2024, Open forum infectious diseases, 11(11) (11), ofae610, English, International magazine[Refereed]Scientific journal
- PURPOSE: While nirmatrelvir/ritonavir (NMV-r) has been positioned as a first-line treatment for mild to moderate COVID-19, it has multiple and significant drug-drug interactions (DDIs). The use of NMV-r in Japan has been limited compared to the United States. This study aimed to describe the distribution of DDIs with NMV-r and their management in patients with COVID-19 under the control of a management system for the appropriate use of NMV-r. METHODS: A retrospective observational study was conducted at a Japanese university hospital. The management system included a flowchart for selecting antivirals and a list for reviewing DDI management, based on the National Institutes of Health guidelines and the guidance of the Japanese Society of Pharmaceutical Health Care and Sciences. Patients with mild to moderate COVID-19 and prescribed NMV-r or molnupiravir (MOV) were included. The primary outcome was DDI management practices, including the selected COVID-19 medications. The secondary outcome included the distribution of DDI classification and the 30-day all-cause mortality. RESULTS: This study included 241 patients (median age of 60 years, 112 [46.5%] females), of whom 126 and 115 received NMV-r and MOV, respectively. Of the 241 patients, 145 (60.2%) received concomitant medications that have DDIs with NMV-r. All 30 patients with severe renal impairment or insufficient details on concomitant medications received MOV. Forty-nine patients with concomitant medications required alternative COVID-19 therapy consideration due to DDIs, of whom 42 (85.7%) patients received MOV. Eighty-one patients had concomitant medications requiring temporary adjustment, of whom 44 (54.3%) patients received NMV-r, and 42 of these patients temporarily adjusted these concomitant medications. Five patients with concomitant medications that can continued by monitoring the effects/adverse effects, of whom 4 (80.0%) patients received NMV-r. Seventy-six patients without concomitant medications requiring DDI management, of whom 71 (93.4%) patients received NMV-r. The 30-day all-cause mortality for eligible patients was 0.9% [95% confidence interval, 0.1-3.1]. CONCLUSIONS: Most patients received appropriate antivirals according to the classification of DDIs, and most patients with concomitant medications requiring temporary adjustment received the recommended DDI management. Our management system is effective in promoting the use of NMV-r in the appropriate patients and managing problematic DDIs.Sep. 2024, Journal of pharmaceutical health care and sciences, 10(1) (1), 54 - 54, English, International magazine[Refereed]Scientific journal
- (一社)日本感染症学会, Sep. 2024, 感染症学雑誌, 98(5) (5), 426 - 429, Japanese[Refereed]
- Monovalent Omicron XBB.1.5 mRNA vaccines were newly developed and approved by the FDA in Autumn 2023 for preventing COVID-19. However, clinical efficacy for these vaccines is currently lacking. We previously established the quantification of antigen-specific antibody sequence (QASAS) method to assess the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the coronavirus antibody database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of monovalent XBB.1.5 vaccines. We analyzed repeated blood samples of healthy volunteers before and after monovalent XBB.1.5 vaccination (BNT162b2 XBB.1.5 or mRNA-1273.815) for the BCR repertoire to assess BCR/antibody sequences that matched SARS-CoV-2-specific sequences in the database. The number of matched unique sequences and their total reads quickly increased 1 week after vaccination. Matched sequences included those bound to the Omicron strain and Omicron XBB sublineage. The antibody sequences that can bind to the Omicron strain and XBB sublineage revealed that the monovalent XBB.1.5 vaccines showed a stronger response than previous vaccines or SARS-CoV-2 infection before the emergence of XBB sublineage. The QASAS method was able to demonstrate the immunogenic effect of monovalent XBB.1.5 vaccines for the 2023-2024 COVID-19 vaccination campaign.Aug. 2024, EJHaem, 5(4) (4), 661 - 668, English, International magazine[Refereed]Scientific journal
- A monovalent Omicron XBB.1.5 mRNA RBD analogue vaccine, MAFB-7256a (DS-5670d), was newly developed and approved in Japan in the Spring of 2024 for the prevention of COVID-19. However, clinical efficacy data for this vaccine are currently lacking. We previously established the Quantification of Antigen-specific Antibody Sequence (QASAS) method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assays and the Coronavirus Antibody Database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of MAFB-7256a. We analyzed repeated blood samples using the QASAS method from three healthy volunteers before and after MAFB-7256a vaccination. BCR response increased rapidly one week post-vaccination and then decreased, as with conventional vaccine. Notably, the matched sequences after MAFB-7256a vaccination specifically bound to the receptor-binding domain (RBD), with no sequences binding to other epitopes. These results validate that MAFB-7256a is an effective vaccine that exclusively induces antibodies specific for the RBD, demonstrating its targeted immunogenic effect.Lead, Jul. 2024, Frontiers in immunology, 15, 1468760 - 1468760, English, International magazine[Refereed]Scientific journal
- This report highlights two cases of surgical site infections (SSIs) caused by Mycobacterium fortuitum (Mf) following abdominal mesh implantation. The first case involved an 83-year-old male experiencing non-healing erythema and wounds post-operation, which persisted despite multiple treatments, until effective management was achieved with targeted antibiotics after Mf identification. The second case concerned a female patient with a gynecological postoperative hernia, where Mf was quickly detected following SSI onset three weeks after surgery. Prompt mesh removal and appropriate antibiotic treatment led to a rapid and full recovery. These cases emphasize the importance of early detection and intervention in managing Mf infections effectively, illustrating how the timing of diagnosis can significantly influence treatment outcomes.May 2024, Cureus, 16(5) (5), e61263, English, International magazine[Refereed]Scientific journal
- Epstein-Barr virus (EBV) reactivation in COVID-19 patients has been reported, but studies on its clinical significance are lacking. We herein report the occurrence of infectious mononucleosis (IM) due to EBV reactivation in a 60-year-old man with rheumatoid arthritis being treated with methotrexate and tocilizumab. The patient presented with a fever and tested positive for COVID-19. Laboratory findings revealed an increased atypical lymphocyte count, decreased platelet count, and elevated liver enzyme levels. Flow cytometry showed predominant expansion of reactive T cells. EBV reactivation was confirmed using real-time polymerase chain reaction. The patient was treated with remdesivir, and clinical improvement was observed after 10 days of treatment. Follow-up showed a gradual decrease in the EBV-DNA load with no recurrence of atypical lymphocytes. These findings suggest that COVID-19 in immunocompromised patients may lead to unexpected EBV reactivation and IM, even for patients outside the age at which IM is likely to occur.Apr. 2024, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 30(11) (11), 1182 - 1185, English, International magazine[Refereed]Scientific journal
- The use of anti-SARS-CoV-2 antibody products like tixagevimab/cilgavimab represents an important strategy to protect immunocompromised patients with haematological malignancies from COVID-19. Although patients who receive these agents should still be vaccinated, the use of tixagevimab/cilgavimab can mask the production of anti-spike antibody after vaccination, making it hard to assess vaccine response. We have newly established a quantification method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the Coronavirus Antibody Database (CoV-AbDab). Repeated blood samples before and after vaccination were analysed for the BCR repertoire, and BCR sequences were searched in the database. We analysed the number and percentage frequency of matched sequences. We found that the number of matched sequences increased 2 weeks after the first vaccination and quickly decreased. Meanwhile, the number of matched sequences more rapidly increased after the second vaccination. These results show that the postvaccine immune response can be assessed at the mRNA level by analysing the fluctuation in matching sequences. Finally, BCR repertoire analysis with CoV-AbDab clearly demonstrated the response to mRNA SARS-CoV-2 vaccination even after tixagevimab/cilgavimab administration in haematological malignancy patients who underwent allogeneic haematopoietic stem cell transplantation.Jun. 2023, British journal of haematology, 202(3) (3), 504 - 516, English, International magazine[Refereed]Scientific journal
- PURPOSE: Many effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed, but a weaker response in individuals undergoing anticancer treatment has been reported. This study evaluates the immunogenic status and safety of SARS-CoV-2 vaccines for patients with non-small-cell lung cancer (NSCLC), receiving tegafur-uracil (UFT) as postoperative adjuvant chemotherapy. METHODS: The subjects of this prospective study were 40 patients who underwent surgery for NSCLC and received SARS-CoV-2 vaccines postoperatively. We compared the antibody titers of SARS-CoV-2 vaccines and the adverse events between patients who received adjuvant UFT and patients who did not. RESULTS: The mean anti-S1 IgG titers were not significantly different between the UFT and without-UFT groups (mean optimal density, 0.194 vs. 0.205; P = 0.76). Multivariate analysis identified the period after the second vaccination as an independent predictor of anti-S1 IgG titer (P = 0.049), but not the UFT status (with or without-UFT treatment; P = 0.47). The prevalence of adverse events did not differ significantly between the groups, and no severe adverse events occurred. CONCLUSIONS: The efficacy and safety of the SARS-CoV-2 vaccines for NSCLC patients who received postoperative adjuvant UFT chemotherapy were comparable to those for NSCLC patients who did not receive postoperative adjuvant UFT chemotherapy. CLINICAL TRIAL REGISTRATION: This study was registered with the University Hospital Medical Information Network (UMIN) in Japan (UMIN000047380).Feb. 2023, Surgery today, 53(9) (9), 1 - 7, English, Domestic magazine[Refereed]Scientific journal
- Objectives: Rapid plasma reagin (RPR) and Treponema pallidum (TP) antibody test kits are often used to diagnose syphilis, although the relationship between their measured values is unclear. We aimed to reveal the relevance of these kits' results. Design and methods: In all, 143 sera from 110 patients were tested using 12 TP kits and 5 RPR kits and the results compared. Results: The specificity and sensitivity of RPR kits were 81-96% and 95-100%, respectively. The correlation coefficients (0.849-0.934) considerably differed between the manual RPR card test and latex agglutination (LA) assay kits. The following sensitivities were obtained: 82-91% for TP fluorescent treponemal antibody absorption assay (FTA-ABS), TP hemagglutination assay (HA), and TP particle agglutination assay (PA); 94-95% for TP LAs; and 92-100% for chemiluminescent immunoassay (CLIA), chemiluminescent enzyme immunoassay (CLEIA), and immunochromatography assay (IC). Correlation coefficients between TP kits were 0.753-0.974, and the measured values varied. Changes in RPR and quantifiable TP kits were the same for patients with reinfected syphilis and with syphilis under treatment. Conclusions: RPR tests had lower specificity than TP antibody tests. RPR card test and RPR LAs had similar specificity and sensitivity, but their measured values were different. RPR should be measured using automatic RPR LA without setting the upper limit of the reported value. RPR LA should also be standardized. The sensitivity of TP antibody was better in CLIA, CLEIA, and IC than in FTA-ABS, HA, PA, and LA. Therefore, TP antibody kits should be standardized and quantified.Nov. 2022, Practical laboratory medicine, 32, e00302, English, International magazine[Refereed]Scientific journal
- We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of BNT162b2. Following the exclusion of three patients because of the development of COVID-19 (n = 2) and loss to follow-up (n = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [n = 15] and mRNA-1273 [n = 7]). Median age at the time of the first vaccination was 56 (range, 23-71) years. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone (n = 1), steroids alone (n = 2), or CI combined with steroids (n = 2). Twenty-one patients (95%) seroconverted after the third dose. None of our patients had serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients.Oct. 2022, Vaccines, 10(11) (11), English, International magazine[Refereed]Scientific journal
- Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells, but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for the S1 protein after a third vaccination in 22 patients treated with the anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving the seroconversion rate in patients treated with the anti-CD20 antibody who failed standard two-dose vaccination.Jun. 2022, Vaccines, 10(6) (6), English, International magazine[Refereed]Scientific journal
- BACKGROUND: Cutibacterium modestum was named in 2020. C. modestum was previously called Propionibacterium humerusii. Several implant-associated infections caused by Cutibacterium species have been previously reported, but native vertebral osteomyelitis due to these bacteria has rarely been reported. CASE PRESENTATION: A 72-year-old man, who had previously received several nerve block injections for low back pain, was referred to our hospital for deterioration in back pain in the last 1 month. MRI findings were suggestive of L5-S1 vertebral osteomyelitis. Blood cultures and bone biopsy culture revealed the presence of Gram-positive bacilli. The isolate was identified as C. modestum by 16SrRNA gene sequencing. A diagnosis of vertebral osteomyelitis caused by C. modestum was made. Minocycline followed by oral amoxicillin was administered for 3 months. His symptom improved and did not recur after treatment completion. CONCLUSION: A case of vertebral osteomyelitis caused by C. modestum was encountered. Although C. modestum is very similar to C. acnes, it could be accurately identified by 16SrRNA gene sequencing. This case represents the first documented C. modestum infection in humans.Corresponding, Apr. 2022, BMC infectious diseases, 22(1) (1), 367 - 367, English, International magazine[Refereed]Scientific journal
- Patients who have undergone hematopoietic stem cell transplantation (HSCT) for hematological disease experience high mortality when infected by coronavirus disease 2019 (COVID-19). However, the safety and efficacy of the COVID-19 vaccine in HSCT patients remain to be investigated. We prospectively evaluated the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) in 25 Japanese allogeneic HSCT patients in comparison with 19 healthy volunteers. While anti-S1 antibody titers in almost all healthy volunteers after the second dose were higher than the cut-off value reported previously, levels in HSCT patients after the second dose were diverse. Nineteen patients (76%) had seroconversion of anti-S1 IgG. The median optical density of antibody levels in HSCT patients with low IgG levels (<600 mg/dL), steroid treatment, or low lymphocytes (<1000/μL) was significantly lower than that in the other HSCT patients. There were no serious adverse events (>Grade 3) and no new development or exacerbation of graft-versus-host disease after vaccination. We concluded that the BNT162b2 mRNA vaccine is safe and effective in Japanese allogeneic HSCT patients.Jan. 2022, Vaccines, 10(2) (2), English, International magazine[Refereed]Scientific journal
- We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.Jan. 2022, International journal of hematology, 115(1) (1), 7 - 10, English, Domestic magazine[Refereed]Scientific journal
- BACKGROUND: Although COVID-19 severity in cancer patients is high, the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing chemotherapy for solid cancers in Japan have not been reported. METHODS: We investigated the safety and immunogenicity of BNT162b2 in 41 patients undergoing chemotherapy for solid cancers and in healthy volunteers who received 2 doses of BNT162b2. We evaluated serum IgG antibody titers for S1 protein by ELISA at pre-vaccination, prior to the second dose and 14 days after the second vaccination in 24 cancer patients undergoing cytotoxic chemotherapy (CC group), 17 cancer patients undergoing immune checkpoint inhibitor therapy (ICI group) and 12 age-matched healthy volunteers (HV group). Additionally, inflammatory cytokine levels were compared between the HV and ICI groups at pre and the next day of each vaccination. RESULTS: Anti-S1 antibody levels were significantly lower in the ICI and CC groups than in the HV group after the second dose (median optimal density: 0.241 [0.063-1.205] and 0.161 [0.07-0.857] vs 0.644 [0.259-1.498], p = 0.0024 and p < 0.0001, respectively). Adverse effect profile did not differ among the three groups, and no serious adverse event occurred. There were no differences in vaccine-induced inflammatory cytokines between the HV and ICI groups. CONCLUSION: Although there were no significant differences in adverse events in three groups, antibody titers were significantly lower in the ICI and CC groups than in the HV group. Further protection strategies should be considered in cancer patients undergoing CC or ICI.Dec. 2021, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 28(4) (4), 516 - 520, English, International magazine[Refereed]Scientific journal
- Serum Cytokine Profiles of Rapid Recovery Patients with COVID-19: Series of 6 Cases.COVID-19 patients reveal various clinical manifestations; however, the specific mechanisms and factors contributing to rapid recovery remain unclear. We performed serum cytokine profiling using a bead-based immunoassay in six COVID-19 patients with mild symptoms who experienced rapid recovery. All patients had fever that resolved within 4 days. During the study, the interferon gamma-related protein 10 (IP-10) level rapidly increased initially, and then rapidly decreased in all six patients. Similarly, the interferon (IFN)-λ 2/3 levels rapidly increased initially, and then decreased in five of the six patients. IP-10 and IFN-λ2/3 may play a key role in the rapid recovery of mild COVID-19.Oct. 2021, The Kobe journal of medical sciences, 67(2) (2), E55-E60, English, Domestic magazine[Refereed]Scientific journal
- Background: Antibody production is one of the primary mechanisms for recovery from coronavirus disease 2019 (COVID-19). It is speculated that massive clonal expansion of B cells, which can produce clinically meaningful neutralizing antibodies, occurs in patients who recover on the timing of acquiring adaptive immunity. Methods: To evaluate fluctuations in clonal B cells and the size of the clones, we chronologically assessed the B-cell receptor (BCR) repertoire in three patients with COVID-19 who recovered around 10 days after symptom onset. Results: We focused on the three dominant clonotypes (top 3) in each individual. The percentage frequencies of the top 3 clonotypes increased rapidly and accounted for 27.8 % on day 9 in patient 1, 10.4 % on day 12 in patient 2, and 10.8 % on day 11 in patient 3, respectively. The frequencies of these top 3 clonotypes rapidly decreased as the patients' clinical symptoms improved. Furthermore, BCR network analysis revealed that accumulation of clusters composed of similar complementarity-determining region 3 (CDR3) sequences were rapidly formed, grew, and reached their maximum size around 10 days after symptom onset. Conclusions: BCR repertoire analysis revealed that a massive surge of some unique BCRs occurs during the acquisition of adaptive immunity and recovery. The peaks were more prominent than expected. These results provide insight into the important role of BCRs in the recovery from COVID-19 and raise the possibility of developing neutralizing antibodies as COVID-19 immunotherapy.Aug. 2021, Heliyon, 7(8) (8), e07748, English, International magazine[Refereed]Scientific journal
- Both the inactivated hepatitis A vaccine (Aimmugen) and purified chick embryo cell rabies vaccine (PCECV, Rabipur) are well tolerated. Anaphylaxis has rarely been reported as an adverse reaction of these vaccines. There have been no reports or published case reports of anaphylaxis due to Aimmugen. According to the Japanese Ministry of Health, Labour and Welfare Aimmugen adverse reaction report, no cases of anaphylaxis have been reported from April 2013 to August 2016. Twenty cases of anaphylaxis due to PCECV (RabAvert) have been reported from 1997 to 2005 in USA, whereas 2 cases have been reported from 2006 to 2016. We report a case of anaphylaxis after multiple vaccinations in a 24-year-old man with ulcerative colitis, previous medical history of tonsillectomy for IgA nephropathy and no history of allergies.Corresponding, Jan. 2021, BMJ case reports, 14(1) (1), English, International magazine[Refereed]Scientific journal
- (一社)日本臨床微生物学会, Dec. 2020, 日本臨床微生物学会雑誌, 31(Suppl.1) (Suppl.1), 204 - 204, Japanesemodified Carbapenem Inactivation Method(mCIM)が陰性を示したGES-5保有Serratia marcescensの一例
- BACKGROUND: Infective endocarditis (IE) is associated with significant morbidity and mortality, and successful management requires expertise in both cardiac surgery and infectious disease (ID). However, the impact of ID consultation on the clinical outcomes of IE is not clear. METHODS: The present study was a quasi-experimental, interrupted time series analysis of the clinical outcomes of patients with IE before (April 1998-April 2008) and after (May 2008-March 2019) the establishment of an ID department at a tertiary care hospital in Japan. The primary outcome was clinical failure within 90 days, defined as a composite of all-cause mortality, unplanned cardiac surgery, new-onset embolic events, and relapse of bacteremia caused by the original pathogen. RESULTS: Of 238 IE patients, 59 patients (25%) were treated in the pre-intervention period, and 179 patients (75%) were treated in the post-intervention period. Establishment of an ID department was associated with a 54% reduction in clinical failure (relative risk, 0.46; 95% confidence interval, 0.21-1.02; P=0.054) and a 79% reduction in new-onset embolic events (relative risk, 0.21; 95% confidence interval, 0.07-0.71; P=0.01). In addition, the rate of inappropriate IE management significantly decreased (relative risk, 0.06; 95% confidence interval, 0.02-0.22; P<0.01). CONCLUSIONS: Establishment of an ID department at a tertiary care hospital was associated with improved management, better clinical outcomes, and reduced embolic events in patients with IE admitted to the hospital.Last, Nov. 2020, The Annals of thoracic surgery, 112(4) (4), 1228 - 1234, English, International magazine[Refereed]Scientific journal
- (一社)日本臨床微生物学会, Jun. 2020, 日本臨床微生物学会雑誌, 30(3) (3), 127 - 134, Japanese[Refereed]
- (一社)日本臨床微生物学会, Jun. 2020, 日本臨床微生物学会雑誌, 30(3) (3), 127 - 134, Japaneseカルバペネマーゼ鑑別ディスクMASTDISCS combi Carba plusの有用性に関する検討[Refereed]
- Congenital syphilis may lead to severe sequelae in affected infants. The prevalence of syphilis in women of childbearing age has increased worldwide. From 2015 to 2018, we encountered eight pregnant women with syphilis including six with late latent and two with early latent syphilis. Seven pregnant women with syphilis received antibiotic therapies of oral amoxicillin, intravenous penicillin G, or the both. The syphilotherapies in four cases were considered effective, because rapid plasma reagin titers decreased. None of the seven pregnant women who received syphilotherapies had congenital syphilis. The remaining one woman who did not undergo a maternity checkup or syphilotherapy delivered a stillbirth with congenital syphilis at 29 gestational weeks.Mar. 2020, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 26(3) (3), 298 - 300, English, International magazine[Refereed]
- (NPO)日本呼吸器外科学会, Jan. 2020, 日本呼吸器外科学会雑誌, 34(1) (1), 57 - 61, Japanese, Domestic magazine[Refereed]Scientific journal
- (一社)日本臨床微生物学会, Dec. 2019, 日本臨床微生物学会雑誌, 30(Suppl.1) (Suppl.1), 229 - 229, Japanese尿検体輸送用容器Uriswabの保存安定性に関する検討[Refereed]
- 日本臨床検査医学会, Oct. 2019, 臨床病理, 67(補冊) (補冊), 143 - 143, Japanese梅毒診断患者を対象とした梅毒検査方法間の判定比較[Refereed]
- 日本臨床検査医学会, Oct. 2019, 臨床病理, 67(補冊) (補冊), 291 - 291, Japanese血液培養液からのメチシリン耐性遺伝子迅速報告の有用性[Refereed]
- PURPOSE: This study aimed to evaluate the efficacy of an educational intervention on reducing the inappropriate use of oral third-generation cephalosporins, the prevalence of resistant bacteria, and clinical outcomes. METHODS: A before-after study was conducted to compare the data for 1 year before and after intervention at a Japanese university hospital. Educational intervention included lectures for all medical staff on oral antibiotics and educational meetings with each medical department. The primary outcome was the use of oral third-generation cephalosporins in inpatients as measured by the monthly median days of therapy (DOTs) per 1000 patient days. Secondary outcomes included the use of each oral antibiotic in inpatients and outpatients, proportion of β-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae (BLNAR), penicillin-resistant Streptococcus pneumoniae (PRSP) and extended-spectrum β-lactamase producing Escherichia coli (ESBLEC), the incidence of hospital-acquired Clostridioides difficile infection (HA-CDI), and hospital mortality. RESULTS: The use of oral third-generation cephalosporins in inpatients was significantly decreased after intervention [DOTs (interquartile range): 24.2 (23.5-25.1) vs. 3.7 (0.0-7.1), P < 0.001], and the value in outpatients was also decreased significantly. The use of fluoroquinolones and macrolides did not increase after intervention. The proportion of BLNAR, PRSP and ESBLEC did not change significantly during the study period. The incidence of HA-CDI was significantly decreased, and hospital mortality did not change after intervention. CONCLUSION: Educational intervention was effective in reducing the use of oral third-generation cephalosporins without increasing the use of broad-spectrum antibiotics and worsening clinical outcome. The prevalence of resistant bacteria did not change during the study period.Oct. 2019, Infection, 47(6) (6), 1037 - 1045, English, International magazine[Refereed]Scientific journal
- BACKGROUND: There are many side effects of antituberculous drugs, however, renal failure is relatively rare. Therefore, this side effect is thought to be unrecognized by most physicians. We experienced one case of acute renal failure caused by antituberculous therapy (rifampicin). CASE REPORT: A 64-year-old Japanese male developed tuberculous pleuritis. Six weeks after starting isoniazid (INH), rifampicin (RFP), and ethambutol (EB), his renal function worsened. We temporarily stopped antituberculous therapy, but the patient's renal failure did not improve, and he was admitted to our hospital for renal biopsy. Renal pathology indicated a diagnosis of acute interstitial nephritis. After starting prednisolone, his renal function slowly improved while INH was continued. A drug-induced lymphocyte stimulation test (DLST) of the antituberculous drugs did not reveal the causative agent. However, we consider RFP to be the most likely culprit. CONCLUSION: In recent reports, renal failure is not a rare complication during antituberculous treatment in the elderly population. Physicians who are involved with the administration of antituberculous therapy have to be aware of this side effect. DLST is not useful for identifying the causative agent of antituberculous drug side effects. Leukocyte migration test may be more useful than DLST for this purpose, but further clinical studies are necessary to verify effectiveness. .May 2019, International journal of clinical pharmacology and therapeutics, 57(5) (5), 264 - 269, English, International magazine[Refereed]Scientific journal
- (一社)日本臨床微生物学会, Dec. 2018, 日本臨床微生物学会雑誌, 29(Suppl.1) (Suppl.1), 393 - 393, Japaneseシカジーニアス分子疫学解析POTキットC.difficileの有用性についての検討[Refereed]
- BACKGROUND: Mycotic aneurysm is an uncommon disease which could be fatal without appropriate treatment. Although standard therapy for mycotic aneurysms consists of resection of the infected aorta and in situ graft replacement, some treat with endovascular stent-grafting because patients may not tolerate graft replacement due to underlying diseases. There are 6 more reported cases of mycotic aneurysm caused by Edwardsiella tarda. With the exception of our case, all underwent resection and debridement of the infected aorta or vascular prosthesis. Herein we report the first case ever of mycotic aneurysm caused by E. tarda, successfully treated with stenting and suppressive antibiotic therapy without resection of the infected aorta. CASE PRESENTATION: A 65-year-old Japanese woman with cirrhosis and hepatocellular carcinoma complained of fatigue. Her work up revealed a ruptured aneurysm of the descending aorta. She went through endovascular stent-graft placement. Edwardsiella tarda grew from blood cultures, which led to the diagnosis of mycotic aneurysm. Edwardsiella tarda is a Gram negative bacillus which rarely causes infections in humans. In the case of bacteremia, its mortality is reported to be very high and all reported cases with mycotic aneurysm caused by E. tarda ended up with resection of the infected aorta. CONCLUSION: Our case shows that in the case of mycotic aneurysm caused by E. tarda, endovascular stent-graft placement could be an alternative to in situ graft replacement.May 2018, Annals of clinical microbiology and antimicrobials, 17(1) (1), 21 - 21, English, International magazine[Refereed]Scientific journal
- OBJECTIVE: To evaluate the long-term effects of comprehensive antibiotic stewardship programs (ASPs) on antibiotic use, antimicrobial-resistant bacteria, and clinical outcomes. DESIGN: Before-after study. SETTING: National university hospital with 934 beds. INTERVENTION: Implementation in March 2010 of a comprehensive ASPs including, among other strategies, weekly prospective audit and feedback with multidisciplinary collaboration. METHODS: The primary outcome was the use of antipseudomonal antibiotics as measured by the monthly mean days of therapy per 1000 patient days each year. Secondary outcomes included overall antibiotic use and that of each antibiotic class, susceptibility of Pseudomonas aeruginosa, the proportion of patients isolated methicillin-resistant Staphylococcus aureus (MRSA) among all patients isolated S. aureus, the incidence of MRSA, and the 30-day mortality attributable to bacteremia. RESULTS: The mean monthly use of antipseudomonal antibiotics significantly decreased in 2011 and after as compared with 2009. Susceptibility to levofloxacin was significantly increased from 2009 to 2016 (P = 0.01 for trend). Its susceptibility to other antibiotics remained over 84% and did not change significantly during the study period. The proportion of patients isolated MRSA and the incidence of MRSA decreased significantly from 2009 to 2016 (P < 0.001 and = 0.02 for trend, respectively). There were no significant changes in the 30-day mortality attributable to bacteremia during the study period (P = 0.57 for trend). CONCLUSION: The comprehensive ASPs had long-term efficacy for reducing the use of the targeted broad-spectrum antibiotics, maintaining the antibiotic susceptibility of P. aeruginosa, and decreasing the prevalence of MRSA, without adversely affecting clinical outcome.Apr. 2018, Infection, 46(2) (2), 215 - 224, English, International magazine[Refereed]Scientific journal
- (一社)日本感染症学会, Mar. 2018, 感染症学雑誌, 92(2) (2), 282 - 282, Japanese3次病院においてStaphylococcus aureusのペニシリン感受性結果はどの程度活用されているか
- (一社)日本臨床微生物学会, Mar. 2018, 日本臨床微生物学雑誌, 28(2) (2), 112 - 118, JapaneseScientific journal
- (一社)日本臨床微生物学会, Dec. 2017, 日本臨床微生物学雑誌, 28(Suppl.1) (Suppl.1), 423 - 423, JapaneseMALDIバイオタイパーSepsityperモードによる血液培養からの菌種同定の精度
- (一社)日本臨床微生物学会, Dec. 2017, 日本臨床微生物学雑誌, 28(Suppl.1) (Suppl.1), 508 - 508, JapaneseライサスS4システムを使用したStaphylococcus属に対する薬剤感受性試験の検討
- (一社)日本臨床衛生検査技師会, Nov. 2017, 医学検査, 66(6号) (6号), 649 - 655, Japanese[Refereed]Scientific journal
- 日本感染症学会, Sep. 2017, 感染症学雑誌, 91(5号) (5号), 778 - 784, Japanese感染性心内膜炎合併が疑われたStreptococcus agalactiaeによる播種性感染症の2例[Refereed]Scientific journal
- 日本感染症学会, Jan. 2017, Kansenshogaku Zasshi, 91(1) (1), 14 - 9, JapaneseThe Deveroppment of Screening Methods Using the Disk Diffusion Method for Carbapenemase-producing Enterobacteriaceae.[Refereed]Scientific journal
- Last, Aug. 2016, BMC INFECTIOUS DISEASES, 16(1) (1), 427 - 427, English, International magazine[Refereed]Scientific journal
- Mar. 2016, 感染症学雑誌, 90(臨増) (臨増), 290, Japaneseマイコプラズマ感染を疑った上気道検体からのヒト呼吸器系ウイルス遺伝子の検出と臨床像の後方視的検討Research society
- [Necrotizing Soft Tissue Infection Caused by Serratia marcescens in a Patient Treated with Tocilizumab].We report herein on a case of community-acquired necrotizing soft tissue infection caused by Serratia marcescens. The patient had been treated with prednisolone, tocilizumab and tacrolimus for rheumatoid arthritis. Since Gram staining of the tissue revealed Gram negative rod bacteria, ceftriaxone and clindamycin were administered as empiric therapy. Tissue culture revealed S. marcescens. Ceftriaxone was continued according to the antibiotic sensitivity. She underwent debridement of necrotic tissue and continued ceftriaxone for 17 days. She recovered and was discharged after skin grafting.Jan. 2015, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 89(1) (1), 53 - 5, Japanese, Domestic magazine[Refereed]Scientific journal
- Last, Dec. 2014, MEDICINE, 93(27) (27), e237, English, International magazine[Refereed]Scientific journal
- There is an approach to emergency medicine that is practiced in Japan, called ER-style emergency medicine, which our hospital has adopted. In this approach, emergency-medicine physicians at this hospital are also involved in inpatient care, which is excluded if patients only need organ-specific treatment, such as for a subarachnoid hemorrhage, acute coronary syndrome, etc. Providing care from admission through discharge can provide a suitable educational environment, especially in the care of infectious diseases patients, which involves fundamental concepts such as microbiological diagnosis and de-escalation. As such, this approach by residents can increase their awareness of the many diseases caused by various microorganisms. To investigate this educational methodology, we analyzed a questionnaire survey with residents trained at our hospital. Of the 48 residents, 46 replied, and the answers reflected that training in this ER-style emergency medicine was useful for learning infectious diseases. As such, medical training in ER-style emergency medicine with an infectious diseases specialist can provide an opportunity for residents to learn about common infectious diseases, excluding immunocompromised patients and organ-transplant patients.Japanese Society for Emergency Medicine, Oct. 2014, 日本臨床救急医学会雑誌, 17(5号) (5号), 693 - 698, Japanese[Refereed]Scientific journal
- (一社)日本感染症学会, Sep. 2014, 感染症学雑誌, 88(5) (5), 745 - 745, Japanese腹腔静脈シャントバルブ留置中の肝硬変患者に結核性腹膜炎・喀痰塗抹検査陽性肺結核を認めた1例
- Jul. 2014, JOURNAL OF DIABETES INVESTIGATION, 5(4) (4), 472 - 473, English, Domestic magazine[Refereed]Scientific journal
- (一社)日本感染症学会, May 2014, 感染症学雑誌, 88(3) (3), 358 - 359, Japanese海外渡航中に発症した下痢便から検出されたメニール鞭毛虫(Chilomastix mesnili)感染症例
- (公社)日本化学療法学会, May 2014, 日本化学療法学会雑誌, 62(Suppl.A) (Suppl.A), 242 - 242, Japanese腹腔静脈シャントバルブ留置中の肝硬変患者に結核性腹膜炎・喀痰塗抹検査陽性肺結核を認めた一例
- May 2014, BMC INFECTIOUS DISEASES, 14, 247, English[Refereed]Scientific journal
- Apr. 2014, JOURNAL OF ANTIBIOTICS, 67(4) (4), 311 - 314, English[Refereed]Scientific journal
- Apr. 2014, BMC INFECTIOUS DISEASES, 14, 198, English[Refereed]Scientific journal
- (一社)日本臨床衛生検査技師会, Mar. 2014, 医学検査, 63(2) (2), 221 - 225, Japanese[Refereed]
- Feb. 2014, JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 21(2) (2), E10 - E10, English[Refereed]Scientific journal
- Oct. 2013, JOURNAL OF INFECTION AND CHEMOTHERAPY, 19(5) (5), 969 - 971, English[Refereed]Scientific journal
- Sep. 2013, JOURNAL OF ANTIBIOTICS, 66(9) (9), 511 - 516, English[Refereed]Scientific journal
- 神戸大学都市安全研究センター, Mar. 2013, 神戸大学都市安全研究センター研究報告, 17, 327 - 334, Japanese
- Background: Gingyo-gedoku-san (GGGS) is an herbal medicine approved for upper respiratory infections in Japan. We conducted an open-label, multi-center, prospective trial, comparing GGGS with oseltamivir in patients with influenza and influenza-like illness (ILI) as a pilot study.Japan Primary Care Association, 2013, Gen. Med., 14(1) (1), 13 - 22, English
Methods: Subjects were healthy persons aged between 16 and 40, and were enrolled from January 12, 2010 to March 24, 2011. Fifteen patients were enrolled in this trial (8 and 7 for GGGS and oseltamivir, respectively). RT-PCR was positive for pandemic influenza A (H1N1) in 10 patients. The patients were provided with either GGGS or oseltamivir for 5 days. The primary outcome was mortality and/or hospitalization 7 days after the initial diagnosis. Body temperature and other clinical characteristics were also evaluated.
Results: All patients recovered from illness without complication or hospitalization. The mean time to resolve symptoms for the GGGS and oseltamivir groups was 3.9 days and 3.3 days, respectively (p=0.43). The GGGS group appeared to have a smaller symptom score AUC than the oseltamivir group, (p=0.26). Time to recover activity level appeared to be shorter in the GGGS group (p=0.10), with shorter time to recover health status (p=0.02). Sub-group analysis on patients with positive PCR showed similar results between the two groups.
Conclusion: GGGS was associated with symptom improvements resembling oseltamivir for both influenza and ILI. Randomized controlled trials involving larger sample sizes are needed to confirm these results. - Japanese Society for Cancer Chemotherapy, 2013, Journal of Infection and Chemotherapy, 19(5) (5), 969 - 971, English[Refereed]Scientific journal
- Oct. 2012, JOURNAL OF INFECTION AND CHEMOTHERAPY, 18(5) (5), 734 - 740, English[Refereed]Scientific journal
- Apr. 2012, SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 44(4) (4), 270 - 275, English[Refereed]Scientific journal
- A 23-year old female was referred to our clinic for intermittent fever occurring over a period of eight years. Every time she developed fever, blood examination revealed elevated leukocytes and C-reactive protein (CRP). Antibiotics were always given based on elevated CRP with apparent improvement. However, the pattern of periodicity with absence of symptoms in between suggested periodic fever syndrome, particularly Familial Mediterranean Fever (FMF), which was later confirmed by mutation analysis. In Japan there is a tendency to use antibiotics solely based on "elevated CRP"; however, careful review of patient history is essential to identify FMF while avoiding the use of unnecessary antibiotics.Japan Primary Care Association, Jun. 2011, Gen. Med., 12(1) (1), 29 - 31, English
- (一社)日本感染症学会, Mar. 2011, 感染症学雑誌, 85(2) (2), 193 - 194, Japanese末梢ルート感染にBacillus cereus眼内炎を合併した1例Research society
- 2011, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 48(5) (5), 461 - 5, Japanese, Domestic magazine[Prevention of infectious diseases in older adults].[Invited]
- Dec. 2010, JOURNAL OF INFECTION AND CHEMOTHERAPY, 16(6) (6), 443 - 445, English[Refereed]Scientific journal
- (一社)日本感染症学会, Nov. 2010, 感染症学雑誌, 84(6) (6), 825 - 825, JapaneseSLEの長期経過中に亜急性の経過で皮下膿瘍をきたした1例
- Sep. 2010, JOURNAL OF TRAVEL MEDICINE, 17(5) (5), 356 - 358, English[Refereed]Scientific journal
- Aug. 2010, JOURNAL OF INFECTION AND CHEMOTHERAPY, 16(4) (4), 298 - 300, English[Refereed]Scientific journal
- (一社)日本感染症学会, May 2010, 感染症学雑誌, 84(3) (3), 377 - 378, Japanese当院で経験したGemella属による感染性心内膜炎の1症例
- (一社)日本感染症学会, Mar. 2010, 感染症学雑誌, 84(臨増) (臨増), 279 - 279, Japanese術後の慢性Candida glabrata縦隔炎に対する長期治療の選択に苦慮した一例
- (一社)日本感染症学会, Mar. 2010, 感染症学雑誌, 84(臨増) (臨増), 441 - 441, JapaneseSLEの長期経過中に亜急性の経過で皮下膿瘍をきたした一例
- 2010, INTERNAL MEDICINE, 49(22) (22), 2423 - 2432, English[Refereed]Scientific journal
- 2010, Kobe Journal of Medical Sciences, 56(5) (5), E195 - E203, EnglishHow were the high-fever consultation center perceived by the officers who provided it in Kobe City, during swine-origin influenza a (H1N1) outbreak? A qualitative study utilizing SCQRM[Refereed]Scientific journal
- (一社)日本感染症学会, Mar. 2009, 感染症学雑誌, 83(2) (2), 167 - 167, Japanese紫斑とショックで来院し病歴から推定された病原微生物が血液培養から検出された1例
- Feb. 2009, PEDIATRIC INFECTIOUS DISEASE JOURNAL, 28(2) (2), 166 - 167, English[Refereed]Scientific journal
- The Japanese Society of Internal Medicine, Oct. 2008, Nihon Naika Gakkai Kaishi, 97(10) (10), 2575 - 2575, Japanese
- (一社)日本感染症学会, May 2008, 感染症学雑誌, 82(3) (3), 249 - 249, Japanese血液培養からラセン菌が検出された!その正体は?
- (一社)日本環境感染学会, Jan. 2007, 環境感染, 22(Suppl.) (Suppl.), 175 - 175, Japaneseアウトブレイクのとらえ方と解釈 アウトブレイク事例報告 疫学の視点から Bacillus cereus血流感染症アウトブレイク事例
- 株式会社医学書院, Dec. 2006, medicina, 43(13) (13), 2008 - 2010
- [Group B streptococcal vertebral osteomyelitis following superficial suppurative thrombophlebitis].An 80-year-old woman with type II diabetes mellitus was admitted to hospital with high-grade fever and leg pain for the previous three days. Physical examination revealed marked distention of the peripheral veins in both lower legs and she complained of pain. Spontaneous superficial suppurative thrombophlebitis was diagnosed and transfusion of cefazolin every 8 hours was started immediately after blood cultures. After 48 hours, the distention of the peripheral veins was improved; however, she suffered from a severe back pain thereafter. Two sets of blood culture yielded Group B streptococcus. Therefore the antibiotic was changed to ampicillin every 6 hours. To investigate the cause of back pain, MRI of the lumbar vertebral body was taken. Saggital gadolinium T1-weighted MRI demonstrated a high signal intensity lesion from Th7 to Th11, suggesting vertebral osteomyelitis following Group B streptococcal bacteremia from superficial suppurative thrombophlebitis. One week later, the clinical symptoms mostly disappeared. After six weeks of treatment, she was discharged. Suppurative thrombophlebitis is an inflammation of the vein wall by microorganisms and sometimes causes secondary metastatic abscess. Aging and diabetes are also risk factors for group B streptococcal invasive infection. This case suggests vertebral osteomyelitis should be taken into consideration during the course of group B streptococcal bacteremia in an elderly patient complaining back pain.Sep. 2006, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 43(5) (5), 635 - 8, Japanese, Domestic magazine[Refereed]Scientific journal
- Lead, Jan. 2006, JOURNAL OF BIOCHEMISTRY, 139(1) (1), 129 - 135, English[Refereed]Scientific journal
- Nov. 2001, JOURNAL OF GASTROENTEROLOGY, 36(11) (11), 790 - 791, English[Refereed]
- Mar. 2001, 鐘紡記念病院誌, 16, 17 - 22骨粗鬆症における女性ホルモンの効果について 当院カルシウム外来でのエストラジオール経皮吸収剤の使用経験を中心に
- (一社)日本救急医学会, Dec. 2023, 日本救急医学会雑誌, 34(12) (12), 699 - 699, Japaneseグラム染色における医療従事者と自動染色機(PoCGS)の染色性比較
- (一社)日本臨床微生物学会, Dec. 2023, 日本臨床微生物学会雑誌, 34(Suppl.1) (Suppl.1), 161 - 161, Japanese培養検査以外の微生物検査診断の重要性 肝炎の診断 再活性化も含めて
- (一社)日本臨床微生物学会, Dec. 2023, 日本臨床微生物学会雑誌, 34(Suppl.1) (Suppl.1), 276 - 276, JapaneseRobinsoniella peoriensisによる右大腿骨開放性骨折創部感染症の1例
- (一社)日本臨床微生物学会, Dec. 2023, 日本臨床微生物学会雑誌, 34(Suppl.1) (Suppl.1), 310 - 310, Japanese小腸内細菌増殖症の診療における微生物培養検査についての検討
- (一社)日本臨床微生物学会, Dec. 2023, 日本臨床微生物学会雑誌, 34(Suppl.1) (Suppl.1), 311 - 311, Japanese質量分析装置を用いたカルバペネマーゼ産生腸内細菌目細菌(CPE)の簡易・迅速検出法に関する検討
- (一社)日本臨床微生物学会, Dec. 2023, 日本臨床微生物学会雑誌, 34(Suppl.1) (Suppl.1), 345 - 345, JapaneseTFTイメージセンサーによる,寒天培地を用いた迅速な細菌検出及び薬剤感受性測定法の開発
- (一社)日本臨床検査医学会, Oct. 2023, 日本臨床検査医学会誌, 71(補冊) (補冊), 149 - 149, Japanese医療従事者と自動染色機(PoCGS)のグラム染色の品質比較
- (公社)日本化学療法学会, Jul. 2023, 日本化学療法学会雑誌, 71(4) (4), 524 - 524, Japanese十分な抗菌薬治療なく放射線療法後に改善したMycobacterium abscessus subsp. abscessusの創部感染
- (株)診断と治療社, Mar. 2023, 診断と治療, 111(Suppl.) (Suppl.), 189 - 192, Japanese
- 日本感染症学会・日本化学療法学会, Mar. 2023, 日本感染症学会総会・学術講演会・日本化学療法学会学術集会合同学会プログラム・抄録集, 97回・71回, O - 148, Japanese血液培養陽性検体のグラム染色所見を用いた菌種推定画像AIの研究開発
- 日本感染症学会・日本化学療法学会, Mar. 2023, 日本感染症学会総会・学術講演会・日本化学療法学会学術集会合同学会プログラム・抄録集, 97回・71回, O - 149, Japanese尿グラム染色判読における判読方法や評価者による予測精度の差についての検討
- 日本感染症学会・日本化学療法学会, Mar. 2023, 日本感染症学会総会・学術講演会・日本化学療法学会学術集会合同学会プログラム・抄録集, 97回・71回, P - 033, Japanese習熟度による血液培養陽性検体のグラム染色判読における推定精度の違い
- 日本感染症学会・日本化学療法学会, Mar. 2023, 日本感染症学会総会・学術講演会・日本化学療法学会学術集会合同学会プログラム・抄録集, 97回・71回, P - 158, Japanese十分な抗菌薬治療なく放射線療法後に改善したMycobacterium abscessus subsp.abscessusの創部感染
- (一社)日本臨床微生物学会, Dec. 2022, 日本臨床微生物学会雑誌, 33(Suppl.1) (Suppl.1), 253 - 253, Japanese抗酸菌薬剤感受性プレートブロスミックRGMの性能評価に関する検討
- (一社)日本集中治療医学会, Nov. 2022, 日本集中治療医学会雑誌, 29(Suppl.1) (Suppl.1), 495 - 495, Japanese神戸大学医学部附属病院集中治療室における重症COVID-19患者に対するリハビリテーション医療の現状
- (一社)日本臨床微生物学会, Sep. 2022, 日本臨床微生物学会雑誌, 32(4) (4), 238 - 244, Japanese
- (株)日本医事新報社, Aug. 2022, jmed mook, (81) (81), 34 - 36, Japanese【あなたも名医!微生物の特徴と適切な抗菌薬がわかる!微生物×薬剤クロスリファレンス】(2章)微生物ごとの特徴と薬剤耐性 細菌 Neisseria meningitidis 髄膜炎菌
- (株)日本医事新報社, Aug. 2022, jmed mook, (81) (81), 37 - 39, Japanese【あなたも名医!微生物の特徴と適切な抗菌薬がわかる!微生物×薬剤クロスリファレンス】(2章)微生物ごとの特徴と薬剤耐性 細菌 Neisseria gonorrhoeae 淋菌
- 「産婦人科の進歩」編集室, Aug. 2022, 産婦人科の進歩, 74(3) (3), 466 - 468, Japanese
- (一社)日本医学教育学会, Jul. 2022, 医学教育, 53(Suppl.) (Suppl.), 187 - 187, Japanese基本的技術トレーニング研修における初期臨床研修医に対する医療安全教育の実践
- 2022, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44thSafety and Efficacy of SARS-CoV-2 Vaccine (BNT162b2) in Allogeneic HSCT Patients
- (一社)日本外科感染症学会, Nov. 2021, 日本外科感染症学会雑誌, 18(1) (1), 130 - 130, Japanese
- (株)メディカ出版, Oct. 2021, Emer Log, 34(5) (5), 707 - 711, Japanese
- (一社)日本医療検査科学会, Aug. 2021, 医療検査と自動化, 46(4) (4), 416 - 416, Japaneseマイクロ流路を用いた新型コロナウイルスの新規抗体検査キット
- (株)東京医学社, Aug. 2021, 腎と透析, 91(増刊) (増刊), 485 - 490, Japanese【腎疾患治療薬update】(第2章)慢性腎臓病・透析合併症 感染症 ワクチン
- (株)南江堂, Apr. 2021, 内科, 127(4) (4), 745 - 748, Japanese
- (株)南江堂, Apr. 2021, 内科, 127(4) (4), 754 - 755, Japanese
- (一社)日本感染症学会, Apr. 2021, 感染症学雑誌, 95(臨増) (臨増), 310 - 310, Japanese重複感染したStaphylococcus epidermidisがred herringとなったMycobacterium bovisによるグラフト感染の一例
- (株)羊土社, Apr. 2021, Gノート, 8(3) (3), 518 - 525, Japanese
- (一社)日本臨床微生物学会, Dec. 2020, 日本臨床微生物学会雑誌, 31(Suppl.1) (Suppl.1), 204 - 204, Japanesemodified Carbapenem Inactivation Method(mCIM)が陰性を示したGES-5保有Serratia marcescensの一例
- (一社)日本臨床微生物学会, Dec. 2020, 日本臨床微生物学会雑誌, 31(Suppl.1) (Suppl.1), 242 - 242, Japanese黄色ブドウ球菌菌血症時の抗菌薬選択におけるメチシリン耐性遺伝子検査の有用性
- (一社)日本臨床微生物学会, Dec. 2020, 日本臨床微生物学会雑誌, 31(Suppl.1) (Suppl.1), 249 - 249, JapaneseMycobacterium goodiiによる腹膜透析関連腹膜炎を発症した1例
- (株)東京医学社, Aug. 2020, 腎と透析, 89(別冊 腹膜透析2020) (別冊 腹膜透析2020), 237 - 238, JapaneseMycobacterium abscessusによる腹膜透析カテーテル・トンネル感染症の一例
- (株)日本医事新報社, Jun. 2020, jmed mook, (68) (68), 82 - 86, Japanese【エキスパートたちが教える!ワクチン【総整理】】(3章)疾患別のワクチン情報 B型肝炎
- (一社)日本感染症学会, May 2020, 感染症学雑誌, 94(3) (3), 382 - 383, Japanese感染性と非感染性下痢症の鑑別の実際
- (一社)日本感染症学会, Mar. 2020, 感染症学雑誌, 94(臨増) (臨増), 255 - 255, JapaneseMRSA感染症に対する抗菌薬療法-効果的な抗菌薬の選択を目指して- オキサゾリジノンFirst MRSA感染症にオキサゾリジシン系を選択するセッティングとは
- (一社)日本感染症学会, Mar. 2020, 感染症学雑誌, 94(臨増) (臨増), 273 - 273, JapaneseAIDS患者での結核の初期悪化との鑑別を要したMycobacterium kyorinenseの肝膿瘍
- (一社)日本感染症学会, Mar. 2020, 感染症学雑誌, 94(臨増) (臨増), 320 - 320, Japaneseセフトリアキソンでノカルジア症を治療する条件とは移植と免疫抑制剤がもたらす困難
- (一社)日本感染症学会, Mar. 2020, 感染症学雑誌, 94(臨増) (臨増), 328 - 328, Japanese髄膜炎菌による化膿性脳室炎 その治療戦略とは
- (一社)日本内分泌学会, Oct. 2019, 日本内分泌学会雑誌, 95(2) (2), 711 - 711, Japanese重症ニューモシスチス肺炎を呈した異所性ACTH症候群の一例
- (一社)日本医学教育学会, Jul. 2019, 医学教育, 50(Suppl.) (Suppl.), 154 - 154, Japanese新規採用初期臨床研修医を対象とした基本的技術トレーニング研修の取り組み
- 2019, INTENSIVIST, 11(1) (1), 110 - 114, Japanese重症感染症とred eyeIntroduction commerce magazine
- Nov. 2018, INFECTION CONTROL, 27(11号) (11号), 1071 - 1076, Japanese【イラスト&研修後の復習クイズつき!インフルエンザとノロウイルス対策 誰でも使えるスマートマニュアル】 準備編 インフルエンザの予防接種と予防投薬の管理Introduction commerce magazine
- Oct. 2018, jmed mook, (58号) (58号), 103 - 115, Japanese【外来でどう診る?性行為感染症 プライマリケア医の悩み・疑問に答えます】 (2章)各疾患の診かた プライマリケア医が診る際のポイントとコツ 性行為によって感染する原虫・蠕虫症と外部寄生節足動物Introduction commerce magazine
- Oct. 2018, jmed mook, (58号) (58号), 9 - 17, Japanese【外来でどう診る?性行為感染症 プライマリケア医の悩み・疑問に答えます】 (1章)プライマリケアで性行為感染症を診る際に必要な基本的知識 性行為感染症の一般的な予防Introduction commerce magazine
- Oct. 2018, jmed mook, (58号) (58号), 1 - 8, Japanese【外来でどう診る?性行為感染症 プライマリケア医の悩み・疑問に答えます】 (1章)プライマリケアで性行為感染症を診る際に必要な基本的知識 性行為感染症とはIntroduction commerce magazine
- Oct. 2018, jmed mook, (58号) (58号), 26 - 34, Japanese【外来でどう診る?性行為感染症 プライマリケア医の悩み・疑問に答えます】 (1章)プライマリケアで性行為感染症を診る際に必要な基本的知識 患者層ごとの性行為感染症対策Introduction scientific journal
- (一社)日本性感染症学会, Sep. 2018, 日本性感染症学会誌, 29(1) (1), 144 - 144, JapaneseHIV感染症に合併した梅毒性乾癬の1例
- Jun. 2018, 薬局, 69(7号) (7号), 2560 - 2565, Japanese【訪日外国人数増加と輸入感染症 外国人患者対応のエッセンス】 感染症を見逃さない・対応するための知識とノウハウ 性感染症[Invited]Introduction commerce magazine
- May 2018, 腎と透析, 84(増刊) (増刊), 283 - 286, Japanese【腎と透析ベッドサイド検査事典】 (第10章)感染マーカー、感染症検査 結核バイオマーカー[Invited]Introduction commerce magazine
- 日本皮膚科学会-大阪地方会・京滋地方会, Apr. 2018, 皮膚の科学, 17(2) (2), 120 - 121, JapaneseHIV感染症に合併した梅毒性乾癬の1例
- 2018, 日本感染症学会西日本地方会学術集会・日本感染症学会中日本地方会学術集会・日本化学療法学会西日本支部総会合同開催プログラム・抄録集, 88th-61st-66thライサスS4を使用したブドウ糖非発酵菌の薬剤感受性試験の検討
- 南江堂, May 2017, 内科, 119(5号) (5号), 943 - 946, Japanese【海外に行くと言われたら-渡航前後の医学的問題について】渡航にまつわる思いがけない問題 留学先に提出するワクチン接種歴の証明[Invited]Introduction commerce magazine
- 日本医事新報社, Nov. 2016, 日本医事新報, (4831号) (4831号), 42 - 46, Japanese【外来でHIV感染症に出会ったとき、どう対応する?】 HIV感染症の告知と専門医療機関への紹介[Invited]Introduction commerce magazine
- Sep. 2016, 臨床病理, 64(補冊) (補冊), SY9 - 2, Japanese体腔液検査 細胞から病態まで 内科診断における体腔液検査の意義[Invited]Meeting report
- Aug. 2016, レジデントノート, 18(8号) (8号), 1548 - 1553, Japanese【もっと診断に直結する!検査の選び方、活かし方Update 臨床の疑問を解決し、賢く検査を使いこなす!】 (第3章)検査のここが知りたい 無菌性髄膜炎をみたらどんな疾患を考えるか?Introduction commerce magazine
- Aug. 2016, INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 49, 71 - 79, English, International magazine[Refereed]
- Jun. 2016, Medicina, 53(7号) (7号), 1028 - 1029, Japanese【抗菌薬の考え方,使い方-ホントのところを聞いてみました】 腹腔内感染症 膵炎Introduction commerce magazine
- May 2016, 日本化学療法学会雑誌, 64(Suppl.A) (Suppl.A), 172, Japanese血液分離Candida属の薬剤感受性 キャンディン系薬に着目してMeeting report
- May 2016, 日本化学療法学会雑誌, 64(Suppl.A) (Suppl.A), 192, Japaneseノカルジア属臨床分離株の薬剤感受性成績についての検討Meeting report
- May 2016, 日本化学療法学会雑誌, 64(Suppl.A) (Suppl.A), 178, Japaneseカルバペネム耐性腸内細菌科細菌に対するスクリーニング法の検討Meeting report
- Apr. 2016, INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 45, 145 - 145, EnglishSummary international conference
- (一社)日本小児血液・がん学会, Apr. 2016, 日本小児血液・がん学会雑誌, 53(1) (1), 31 - 31, Japanese化学療法後の好中球減少期に血栓性静脈炎によりメチシリン耐性表皮ブドウ球菌の持続菌血症を呈した急性骨髄性白血病の1例Meeting report
- Mar. 2016, 感染症学雑誌, 90(臨増) (臨増), 279, Japanese当院にて経験したMycoplasma hominis感染症例の検討Meeting report
- Mar. 2016, 感染症学雑誌, 90(臨増) (臨増), 254, Japanese消化管穿通をきたした感染性動脈瘤の検討Meeting report
- Mar. 2016, 日本化学療法学会雑誌, 64(2号) (2号), 363, Japanese血液から分離されたPseudomonas aeruginosaに対する各種抗菌薬の薬剤感受性Meeting report
- (一社)日本感染症学会, Mar. 2016, 感染症学雑誌, 90(臨増) (臨増), 244 - 244, JapaneseEdwardsiella tardaによる感染性大動脈瘤の1例Meeting report
- Mar. 2016, 感染症学雑誌, 90(2号) (2号), 185 - 186, JapaneseDPS192iXを使用した薬剤耐性菌早期検出についての検討Meeting report
- Mar. 2016, 感染症学雑誌, 90(臨増) (臨増), 345, JapaneseCalcified amorphous tumorに合併したPropionibacterium acnesによる感染性心内膜炎の一例Meeting report
- Feb. 2016, 化学療法の領域, 32(3号) (3号), 404 - 411, Japanese【臓器障害・生理機能に対応した抗菌薬の適正使用】 特殊な患者に対する抗菌薬の使用方法 種類の選択・用法用量設定・適正使用 肝障害[Invited]Introduction commerce magazine
- 2016, 日本小児血液・がん学会雑誌(Web), 53(1) (1)化学療法後の好中球減少期に血栓性静脈炎によりメチシリン耐性表皮ブドウ球菌の持続菌血症を呈した急性骨髄性白血病の1例
- 南江堂, Nov. 2015, 内科, 116(5号) (5号), 783 - 788, Japanese【すべての内科医のためのHIV感染症-長期管理の時代に】 HIV感染症の合併症 非AIDS指標疾患を中心に ウイルス性肝炎[Invited]Introduction commerce magazine
- Sep. 2015, 臨床透析, 31(10号) (10号), 1255 - 1262, Japanese【老年医学からみた透析医療】 高齢透析患者の感染対策 早期発見とワクチン接種[Invited]Introduction scientific journal
- May 2015, Medicina, 52(6号) (6号), 868 - 871, Japanese【感染症診療 それ,ホント?】 外来編 腸管出血性大腸菌感染症(血清型O157など)に抗菌薬は危険ってホント?[Invited]Introduction commerce magazine
- Apr. 2015, レジデントノート, 17(2号) (2号), 283 - 290, Japanese【新・日常診療での薬の選び方・使い方 日頃の疑問をズバッと解決!】 (第3章)消化器系 慢性ウイルス性肝炎の治療薬について、専門家の意見を教えてください[Invited]Introduction commerce magazine
- Nov. 2014, INFECTION CONTROL, (2014秋季増刊) (2014秋季増刊), 56 - 63, Japanese【"初めてさん"も"自己流さん"も みせて説得!みて納得! 図解でわかる!みんなの感染対策キホンノート】 (1章)全職員向け!感染対策毎日のキホンノート 職業感染予防[Invited]Introduction commerce magazine
- ヴァンメディカル, Sep. 2014, 感染と抗菌薬, 17(3号) (3号), 230 - 238, Japanese【より効果を上げるための抗菌薬治療の攻め時・控え時】 『攻め』の感染症予防策 抗菌薬の予防投与 積極的な実施が求められる場合とは[Invited]Introduction commerce magazine
- Aug. 2014, INFECTION CONTROL, 23(8号) (8号), 803 - 807, Japanese【知っていると知らないとでは大違い!ICTのための感染症診療、やさしく解説-感染症医必携ガイドラインの読みドコロ&勘ドコロ-】 医療従事者のB型肝炎予防 誰に接種するか?[Invited]Introduction commerce magazine
- ヴァン・メディカル, Feb. 2014, 臨床腫瘍プラクティス, 10(1号) (1号), 73 - 77, Japanese【成人白血病に対する治療-治癒を目指して】 白血病薬物治療に関わる特有ぬ有害事象対策 発熱性好中球減少症(Febrile neutropenia:FN)[Invited]Introduction commerce magazine
- Dec. 2013, Hospitalist, 1(2号) (2号), 201 - 208, Japanese【感染症】 治療期間の設定 経静脈投与から経口投与へのスイッチについてのエビデンス[Refereed][Invited]Introduction scientific journal
- 南江堂, Nov. 2013, 内科, 112(5号) (5号), 921 - 924, Japanese【医療関連感染症 起こさないためにどうするか? 起きてしまったらどうするか?】 医療関連感染症の主要な疾患 Clostridium difficile感染症[Invited]Introduction commerce magazine
- 地域医療振興協会, Sep. 2013, 月刊地域医学, 27(9) (9), 806 - 811, JapaneseLocal factorを改善させる地道な活動を地域医療の現場に求む : 地域住民を細菌感染症から守るためにできること
- 南山堂, Aug. 2013, 治療, 95(8号) (8号), 1498 - 1502, Japanese【変わりつつある予防接種-状況に合わせてどのワクチンをすすめるか?-】 特殊な状況におけるワクチン 職業感染対策としてのワクチン[Invited]Introduction commerce magazine
- Jul. 2013, Medicina, 50(7号) (7号), 1154 - 1158, Japanese【"実践的"抗菌薬の使い方-その本質を理解する】 薬剤同士の"同じ部分=類似性"をまとめてその特徴を理解する 対象微生物でまとめる グラム陽性菌用の薬剤[Invited]Introduction commerce magazine
- Jun. 2013, INFECTION CONTROL, 22(6号) (6号), 547 - 548, Japanese【今からできる!抗菌薬の適正使用Tips30】 私たちはこうして成功した!抗菌薬適正使用チームの経験から Big gun projectって何?[Invited]Introduction commerce magazine
- (株)南江堂, Jun. 2013, 内科, 111(6号) (6号), 1415 - 1427, Japanese[Invited]Introduction commerce magazine
- Jun. 2013, 内科, 111(6号) (6号), 1418, Japanese【検査値を読む2013】 感染症検査 ウイルス感染症検査 HBVプレコア/コアプロモーター変異検出[Invited]Introduction commerce magazine
- Jun. 2013, 内科, 111(6号) (6号), 1413 - 1414, Japanese【検査値を読む2013】 感染症検査 ウイルス感染症検査 B型肝炎ウイルス抗体検査[Invited]Introduction commerce magazine
- Mar. 2013, 感染と抗菌薬, 16(1) (1), 67 - 73, Japanese病態・領域からみる敗血症マネジメントの実際「発熱性好中球減少症」[Invited]Introduction commerce magazine
- ヴァンメディカル, Mar. 2013, 感染と抗菌薬, 16(1号) (1号), 67 - 73, Japanese【いま、敗血症をどう治療するか-早期見極めと迅速治療の指針】 病態・領域からみる敗血症マネジメントの実際 発熱性好中球減少症(Febrile neutropenia)Introduction commerce magazine
- Feb. 2013, 救急・集中治療, 25(1) (1), 39 - 45, Japanese骨髄炎[Invited]Introduction commerce magazine
- Feb. 2013, 救急・集中治療, 25(1-2) (1-2), 39 - 45, Japanese【ER・ICUで必要な注射用抗菌薬-エキスパートの考え方と使い方-】 ER・ICUで問題となる感染症 主な原因菌と抗菌薬療法の原則 骨髄炎[Invited]Introduction commerce magazine
- Dec. 2012, Journal of Disaster Research, 7(6) (6), 746 - 753Book review
- Dec. 2012, 救急・集中治療, 24(11-12) (11-12), 1478 - 1481, Japanese【迅速で的確な対応のための重症感染症Q&A-最新の診かたと考え方-】 初期診断から治療まで 疾患別・最新の感染症診療 HIV感染症[Invited]Introduction commerce magazine
- Sep. 2012, Diabetes Journal: 糖尿病と代謝, 40(3号) (3号), 133 - 138, Japanese糖尿病患者に発症し、化膿性脊椎炎と髄膜炎を合併したCampylobacter fetus感染性心内膜炎の1例[Refereed]Introduction commerce magazine
- へるす出版, May 2012, 救急医学, 36(5号) (5号), 546 - 549, Japanese【知っておきたい、見落としやすい、危険な感染症】 アメーバ赤痢[Invited]Introduction scientific journal
- Sep. 2011, 日本老年医学会雑誌, 48巻, 5号, pp. 461-465, Japanese【高齢者の感染症】 予防は治療に勝る 高齢者感染症の予防法Introduction scientific journal
- Sep. 2011, ERマガジン, 8巻, 3号, pp. 487-490, Japanese【ERで遭遇する一般市中感染症の診断と初期対応[後編]】 急性HIV感染症を疑うとき ERで行うべき検査は?Introduction scientific journal
- Sep. 2011, ERマガジン, 8巻, 3号, pp. 491-495, Japanese【ERで遭遇する一般市中感染症の診断と初期対応[後編]】 「海外旅行後に熱が出ました」に驚かずにERで対応するためのアプローチIntroduction scientific journal
- Sep. 2011, ERマガジン, 8巻, 3号, pp. 477-480, Japanese【ERで遭遇する一般市中感染症の診断と初期対応[後編]】 これってインフルエンザ?! インフルエンザにみえる他疾患Introduction scientific journal
- Sep. 2011, ERマガジン, 8巻, 3号, pp. 387-395(2) (2), Japanese【ERで遭遇する一般市中感染症の診断と初期対応[後編]】 ERでの若い女性の発熱、下腹部痛へのアプローチ 頸管炎・PIDの診断・初期治療Introduction scientific journal
- Jul. 2011, 薬局, 62巻, 8号, pp. 2941-2949, Japanese【ワクチン入門】 予防可能な感染症と予防が難しい感染症 成人・高齢者Introduction scientific journal
- (株)メディカ出版, May 2011, INFECTION CONTROL, 巻, 2011春季増刊, pp. 242-243(2011春季増刊) (2011春季増刊), 240 - 241, Japanese【感染対策に役立つ臨床微生物らくらく完全図解マニュアル】 薬剤耐性微生物の基礎知識と対策 薬剤耐性ウイルスIntroduction scientific journal
- 羊土社, Jan. 2011, レジデントノ-ト, 12(14) (14), 2500 - 2504, Japanese無菌性髄膜炎をみたらどんな疾患を考えるか? (診断に直結する検査の選び方、活かし方--無意味な検査をなくし,的確に患者の状態を見抜く!) -- (検査のここが知りたい)
- Jan. 2011, Annual Review呼吸器, 2011巻, , pp. 249-255, Japanese治療の進歩 多剤耐性緑膿菌の治療戦略Introduction scientific journal
- 羊土社, Jan. 2011, レジデントノート, 12巻, 14号, pp. 2500-2504(14) (14), 2505 - 2509, Japanese【診断に直結する検査の選び方、活かし方 無意味な検査をなくし、的確に患者の状態を見抜く!】 検査のここが知りたい 無菌性髄膜炎をみたらどんな疾患を考えるか?Introduction scientific journal
- 医学出版, Jul. 2010, 月刊レジデント, 3巻, 7号, pp. 50-55(7) (7), 56 - 64, Japanese【感染症に強くなる レジデント必須項目と落とし穴】 病態・診断および抗菌薬療法の基本と注意点 成人における骨髄炎Introduction scientific journal
- Apr. 2010, jmed mook, 巻, 7号, pp. 144-151, Japanese【いきなり名医! 見逃したらコワイ外来で診る感染症 感染症診療コツのコツ】 感染症外来診療で絶対知っておきたいマスト15の知識 外来で出会う輸入感染症 丁寧な病歴聴取で渡航時の状況を把握することが鍵Introduction scientific journal
- 羊土社, Oct. 2009, レジデントノ-ト, 11, 87 - 92, Japanese慢性ウイルス性肝炎の治療薬について,専門家の意見を教えてください (日常診療での薬の選び方・使い方--日頃の疑問に答えます) -- (消化器系)
- 羊土社, Jan. 2009, レジデントノ-ト, 10(10) (10), 1499 - 1504, Japanese化膿性椎体炎,化膿性関節炎,急性骨髄炎のDo not--診断の落とし穴 (特集 感染症診断の大原則--なぜ,どこで間違うのか?)
- 羊土社, Sep. 2008, レジデントノ-ト, 10(6) (6), 916 - 922, Japanese主治医として診る 救急からの入院治療(第6回)細菌性髄膜炎の入院へのアプローチ--Time is life
- 照林社, Mar. 2008, エキスパートナース, 24(3) (3), 84 - 89, Japanese「病態生理」でよくわかる ケアに役立つ疾患のハナシ(第15回)尿路感染症
- Oct. 2007, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 22, A163 - A163, EnglishA case of community acquired acute cholangitis caused by Burkholdria cepacia - biliary drainage is mainstay of treatmentSummary international conference
- 南山堂, Sep. 2007, 治療, 89(9) (9), 2567 - 2571, Japanese咳へのアプローチ--抗菌薬の適性使用の観点から (特集 プライマリ・ケア医のための咳嗽の病態と治療)
- 中山書店, Jul. 2007, EBMジャ-ナル, 8(4) (4), 572 - 577, Japanese赤痢アメーバ症のエビデンス (特集 グローバル化時代の輸入感染症,そして旅行医学) -- (これだけは知っておきたい最新事情)
- 羊土社, Feb. 2007, レジデントノ-ト, 8(11) (11), 1527 - 1531, Japanese抗菌薬の併用・広域抗菌薬についてのQ&A--STOP!抗菌薬乱用 (特集 抗菌薬について内心疑問に思っていること)
- 2007, 環境感染, 22(Supplement) (Supplement)アウトブレイク事例報告 疫学の視点から-Bacillus cereus血流感染症アウトブレイク事例-
- 永井書店, Sep. 2002, 綜合臨床, 51(9) (9), 2710 - 2712, Japanese症例 壁外発育伸展をきたした大腸癌の一例
- Editor, 日本医事新報社, Oct. 2018, Japaneseあなたも名医! 外来でどう診る?性行為感染症 プライマリケア医の悩み・疑問に答えます / あなたも名医! 外来でどう診る?性行為感染症 プライマリケア医の悩み・疑問に答えます】Scholarly book
- Others, 東京医学社, May 2018, Japanese腎と透析 ベッドサイド検査辞典 / 第10章 感染マーカー、感染症検査 3、結核バイオマーカーScholarly book
- Others, 文光堂, Feb. 2013, JapaneseStep Up式 感染症診療のコツ / 膿瘍の治療Scholarly book
- Supervisor, 中外医学社, Mar. 2012, Japanese災害ボランティア健康管理マニュアル / 下痢, 抗生物質はいつ飲むのかScholarly book
- Others, ライフサイエンス出版, Mar. 2012, JapaneseJAID/JSC 感染症治療ガイド2011 / 骨髄炎Scholarly book
- Joint translation, メディカルサイエンスインターナショナル, Feb. 2012, Japaneseトラベル・アンド・トロピカル・メディシン・マニュアル / 魚と貝の食中毒:毒素症候群Scholarly book
- Joint work, 南山堂, Nov. 2011, Japanese免疫不全者の呼吸器感染症 / 7、炎症性腸疾患 10、肝疾患Scholarly book
- Joint work, 医学書院, Aug. 2011, Japanese総合診療・感染症科マニュアル / 消化管Scholarly book
- Supervisor, 文光堂, Apr. 2011, Japaneseここが知りたい!!偽膜性腸炎/CDI / CDIが再発する場合Scholarly book
- Joint work, 医学書院, Mar. 2011, Japanese病院内/免疫不全関連感染症診療の考え方と進め方 / 耐性グラム陰性桿菌の治療薬Scholarly book
- Joint translation, 医学書院, Mar. 2011, Japanese感染症のコントラバーシ- / 感染症におけるプロバイオティクスScholarly book
- Joint work, 羊土社, Jan. 2011, Japanese診断に直結する検査の選び方、活かし方 / 無菌性髄膜炎を見たらどんな疾患を考えるか?Scholarly book
- Joint work, 羊土社, Jul. 2010, Japanese主治医として診る 救急からの入院治療 / 細菌性髄膜炎Scholarly book
- Joint work, 羊土社, Nov. 2009, Japanese抗菌薬について内心疑問に思っていることQ&A / 【抗菌薬の併用が必要なのはどのようなときですか?】Scholarly book
- Joint work, 羊土社, Nov. 2009, Japanese抗菌薬について内心疑問に思っていることQ&A / 【ブロードスペクトラム(広域)の抗菌薬は,どのようなときに使うべきなのでしょうか?】Scholarly book
- Joint work, 羊土社, Sep. 2009, Japanese日常診療での薬の選び方 使い方-日頃の疑問に答えます / 慢性ウイルス性肝炎の治療薬について,専門家の意見を教えてくださいScholarly book
- Joint work, 日本医事新報社, Aug. 2009, Japanese専門医を目指すケース・メソッド・アプローチ11 感染症 / 【頭痛を訴え他院を受診,錯乱のためERを受診した33歳男性】Scholarly book
- Joint work, 医学書院, Dec. 2008, Japanese成人看護学〈11〉アレルギー・膠原病・感染症 (系統看護学講座 専門) / 疾患の理解Textbook
- 日本消化器病学会・近畿支部 第77回教育講演会, Feb. 2025「消化器内科医がであう感染症の知識のアップデート」[Invited]
- 第72回日本化学療法学会西日本支部総会, Nov. 2024STDの最近の知見[Invited]
- 29回日本病院総合診療医学会学術総会, Sep. 2024ジョイントプログラム1(集中治療学会)「集中治療×総合診療=∞」[Invited]
- グローバルヘルス合同大会2023, Nov. 2023Rabies post exposure prophylaxis for category 3 Stray dog bite in ThailandPublic symposium
- ASM Microbe, Jun. 2023Research and Development of Image Recognition AI to Estimate Bacterial Species Using Gram Stain Findings in Urine SpecimensPoster presentation
- 第97回日本感染症学会総会, Apr. 2023尿グラム染色判読における判読方法や評価者による予測精度の差についての検討Oral presentation
- 第97回日本感染症学会総会, Apr. 2023血液培養陽性検体のグラム染色所見を用いた菌種推定画像AIの研究開発Oral presentation
- 第34回日本臨床微生物学会総会抗酸菌薬剤感受性プレートブロスミックRGMの性能評価に関する検討Oral presentation
- 日本感染症学会東日本地方会学術集会・日本化学療法学会東日本支部総会 合同学会, Oct. 20222. 尿検体グラム染色像を活用した早期に菌種推定を行う画像AIの研究開発
- 第49回日本集中治療医学会学術集会神戸大学医学部附属病院集中治療室における重症COVID-19患者に対するリハビリテーション医療の現状Oral presentation
- 日本臨床微生物学会学術集会, Jan. 2022グラム染色像を用いて早期に菌種推定を行う画像AIの研究開発Oral presentation
- 第34回日本外科感染症学会, Dec. 2021AI画像解析を利用した外科感染症診療補助システム[Invited]Invited oral presentation
- 救急領域においては、施設ごとに可能な臨床検査体制をしくべきである。, Feb. 2019, Japanese, 東京, Domestic conference救急領域における臨床検査の役割[Invited]Nominated symposium
- 第30回日本臨床微生物学会学術集会, Feb. 2019, Japanese, 日本臨床微生物学会, 東京, 救急領域においては、施設ごとに可能な臨床検査体制をしくべきである。, Domestic conference救急領域における臨床検査の役割[Invited]Nominated symposium
- 第30回日本臨床微生物学会, Feb. 2019, Japanese, 東京, Domestic conferenceシカジーニアス分子疫学解析POTキットC.difficileの有用性についての検討Poster presentation
- PR-3ANCA陽性のみでは血管炎との確定診断をすることは危険である, Nov. 2018, Japanese, 鹿児島, Domestic conference初診時よりPR3ANCA陽性となり当初鑑別困難であった日本紅斑熱の1例Oral presentation
- 第88回日本感染症学会西日本地方会学術集会, Nov. 2018, Japanese, 日本感染症学会, 鹿児島, PR-3ANCA陽性のみでは血管炎との確定診断をすることは危険である, Domestic conference初診時よりPR3ANCA陽性となり当初鑑別困難であった日本紅斑熱の1例Oral presentation
- 第66回日本化学療法学会西日本地方会, Nov. 2018, Japanese, 鹿児島市, Domestic conferenceライサスS4を使用したブドウ糖非発酵菌の薬剤感受性試験の検討Poster presentation
- 第66回日本化学療法学会西日本支部総会, Nov. 2018, Japanese, 鹿児島, Domestic conferenceライサスS4を使用したブドウ糖非発酵菌の薬剤感受性試験の検討Poster presentation
- ボロン酸添加によってClass Cbetalactamaseの影響を排除することでClassB βラクタマーゼ産生を確認することができた, Nov. 2018, Japanese, 鹿児島, Domestic conferencemetallo-beta-lactamase確認試験にボロン酸添加が有用であったVIM型メタロβラクタマーゼ産生緑膿菌の一例Oral presentation
- 第88回日本感染症学会西日本地方会学術集会, Nov. 2018, Japanese, 日本感染症学会, 鹿児島, ボロン酸添加によってClass Cbetalactamaseの影響を排除することでClassB βラクタマーゼ産生を確認することができた, Domestic conferencemetallo-beta-lactamase確認試験にボロン酸添加が有用であったVIM型メタロβラクタマーゼ産生緑膿菌の一例Oral presentation
- 第41回日本母体胎児医学会学術集会, Aug. 2018, Japanese, 東京, Domestic conference梅毒合併妊娠の7症例Oral presentation
- 肺孤立結節型ヒストプラズマ症の診断および外科的治療について発表, May 2018, Japanese, 東京, Domestic conference悪性腫瘍との鑑別を要した肺ヒストプラズマ症の一例Oral presentation
- 第35回日本呼吸器外科学会, May 2018, Japanese, 日本呼吸器外科学会, 東京, 肺孤立結節型ヒストプラズマ症の診断および外科的治療について発表, Domestic conference悪性腫瘍との鑑別を要した肺ヒストプラズマ症の一例Oral presentation
- 第66回日本化学療法学会総会, May 2018, Japanese, 岡山, Domestic conferenceMBL確認試験にボロン酸添加が有用であったVIM型MBL産生緑膿菌の一例Oral presentation
- 第29回日本臨床微生物学会総会, Feb. 2018, Japanese, 日本臨床微生物学会, 岐阜, Domestic conferenceライサスS4 システムを使用したStaphylococcus 属に対する薬剤感受性試験の検討Oral presentation
- 第29回日本臨床微生物学会総会, Feb. 2018, Japanese, 日本臨床微生物学会, 岐阜, Domestic conferenceMALDI バイオタイパーSepsityper モードによる血液培養からの菌種同定の精度Oral presentation
- 第465回日本皮膚科学会大阪地方会, Feb. 2018, Japanese, 大阪地方会, 大阪, Domestic conferenceHIV感染症に合併した梅毒性乾癬の1例Oral presentation
- 第87回日本感染症学会西日本地方会学術集会, Oct. 2017, Japanese, The Japanese Association for Infectious Diseases日本感染症学会, 長崎, 3次病院におけるペニシリン感受性黄色ブドウ球菌菌血症の結果について臨床サイドの利用は30%程度であった, Domestic conference3次病院におけるペニシリン感受性黄色ブドウ球菌菌血症におけるDe-escalationの検討~微生物検査室で黄色ブドウ球菌のペニシリン感受性検査をどこまで行うべきか~Oral presentation
- 2018 International conference on Infectious Disease, Mar. 2017, English, ICID, Buenos Aires, Argentina, Detection of blaZ gene is not available in most laboratory, whereas microdilution technique is available in most laboratory and does not depend technician`s experience. The aim of our study is to compare the sensitivity and specificity of conventional phe, International conferenceComparison of microdilution technique and phenotypic method for the detection of Staphylococcus aureus penicillinase production in JapanPoster presentation
- 第28回日本臨床微生物学会学術集会, Jan. 2017, Japanese, 日本臨床微生物学会, 長崎, Domestic conference当院で分離されたMycobacterium colombiense の一症例についてOral presentation
- 第28回日本臨床微生物学会総会・学術集会, Jan. 2017, Japanese, 日本臨床微生物学会, 長崎, Domestic conference当院で分離されたMycobacterium colombienseの一症例についてOral presentation
- 第28回日本臨床微生物学会総会・学術集会, Jan. 2017, Japanese, 日本臨床微生物学会, 長崎, Domestic conference腸内細菌科細菌におけるModified Carbapenemase Inactivation Method testに関する検討Oral presentation
- 第28回日本臨床微生物学会総会・学術集会, Jan. 2017, Japanese, 日本臨床微生物学会, 長崎, Domestic conference血液培養から検出された表皮ブドウ球菌の薬剤感受性とDaptomycin耐性についてOral presentation
- 第28回日本臨床微生物学会総会・学術集会, Jan. 2017, Japanese, 日本臨床微生物学会, 長崎, Domestic conferenceクロモアガーmSuper CARBAを用いたCPEスクリーニングに関する検討Oral presentation
- 第28回日本臨床微生物学会総会・学術集会, Jan. 2017, Japanese, 日本臨床微生物学会, 長崎, Domestic conferencePOT法を用いた血液培養由来ESBL産生Escherichia coliの疫学解析Oral presentation
- 第86回日本感染症学会西日本地方会学術集会 第59回日本感染症学会中日本地方会学術集会 第64回日本化学療法学会西日本渋総会, Nov. 2016, Japanese, 日本感染症学会・日本化学療法学会, 沖縄, Domestic conference喀痰からCryptococcus neoformans、Bjerkandera adustaが検出されたHelicobacter cinaediによる感染性動脈瘤の一例Oral presentation
- 第86回日本感染症学会西日本地方会学術集会 第59回日本感染症学会中日本地方会学術集会 第64回日本化学療法学会西日本渋総会, Nov. 2016, Japanese, 日本感染症学会・日本化学療法学会, 沖縄, Domestic conferenceカルバペネマーゼ産生腸内細菌科細菌用スクリーニング培地の検討Oral presentation
- 第59回日本感染症学会中日本地方会学術集会, Nov. 2016, Japanese, 日本感染症学会, 沖縄, Domestic conferenceカルバペネマーゼ産生腸内細菌科細菌用スクリーニング培地の検討Oral presentation
- 第65回日本医学検査学会, Sep. 2016, Japanese, 日本臨床衛生検査技師会, 神戸, Domestic conference体腔液検査の意義?感染症医からの視点Public symposium
- 33rd Nordic Society of Clinical Microbiology and Infectious Diseases, Sep. 2016, English, Nordic Society of Clinical Microbiology and Infectious Diseases, Rovaniemi, Finland, International conferenceClinical manifestations of Mycoplasma hominis infection Clinical manifestations of Mycoplasma hominis infectionPoster presentation
- 第64回日本化学療法学会総会, Jun. 2016, Japanese, 日本化学療法学会, 神戸, Domestic conference血液分離Candida属の薬剤感受性ーキャンディン系薬に着目してーOral presentation
- 第64回日本化学療法学会総会, Jun. 2016, Japanese, 日本化学療法学会, 神戸, Domestic conferenceノカルジア属臨床分離株の薬剤感受性成績についての検討Oral presentation
- 第64回日本化学療法学会総会, Jun. 2016, Japanese, 日本化学療法学会, 神戸, Domestic conferenceカルバペネム耐性腸内細菌科細菌に対するスクリーニング法の検討Oral presentation
- 第90回日本感染症学会総会・学術講演会, Apr. 2016, Japanese, 日本感染症学会, 仙台, Domestic conference当院にて経験したMycoplasma hominis 感染症例の検討Oral presentation
- 第90回日本感染症学会総会, Apr. 2016, Japanese, 日本感染症学会, 仙台, Domestic conference当院で経験したMycoplasma hominis感染症例の検討Oral presentation
- 第90回日本感染症学会総会, Apr. 2016, Japanese, 日本感染症学会, 仙台, Domestic conference消化管穿通を来した感染性動脈瘤の検討Oral presentation
- 第90回日本感染症学会総会, Apr. 2016, Japanese, 日本感染症学会, 仙台, Domestic conferenceマイコプラズマ感染を疑った上気道検体からのヒト呼吸器系ウイルス遺伝子の検出と臨床像の後方視的検討Poster presentation
- 第90回日本感染症学会総会, Apr. 2016, Japanese, 日本感染症学会, 仙台, Domestic conferenceEdwardsiella tardaによる 感染性大動脈瘤の1例Oral presentation
- 17th International conference on Infectious diseases, Mar. 2016, English, International conference on Infectious diseases, ハイデラバード, インド, International conferenceClostridium difficile infection at outpatient clinic without known risk factorsPoster presentation
- 第27回臨床微生物学会, Feb. 2016, Japanese, 日本臨床微生物学会, 仙台, Domestic conferenceMALDI-TOF MSと遺伝子検査を組み合わせた薬剤耐性菌迅速同定の試みPoster presentation
- 第27回日本臨床微生物学会総会・学術集会, Jan. 2016, Japanese, 日本臨床微生物学会, 仙台, Domestic conference当院における非結核性抗酸菌の薬剤感受性についてPoster presentation
- 第27回日本臨床微生物学会総会・学術集会, Jan. 2016, Japanese, 日本臨床微生物学会, 仙台, Domestic conferenceライサスエニーを使用した各種β ラクタマーゼ産生腸内細菌に対する薬剤感受性試験の検討Poster presentation
- 第27回日本臨床微生物学会総会・学術集会, Jan. 2016, Japanese, 日本臨床微生物学会, 仙台, Domestic conferenceMALDIバイオタイパーを用いた尿検体からの原因菌直接同定に関する検討Oral presentation
- 第27回日本臨床微生物学会総会・学術集会, Jan. 2016, Japanese, 日本臨床微生物学会, 仙台, Domestic conferenceMALDI-TOF MS を用いた血液培養細菌迅速同定に関する検討Oral presentation
- 第85回日本感染症学会西日本地方会学術集会, Sep. 2015, Japanese, 日本感染症学会, 奈良, Domestic conferenceDPS192iXを使用した薬剤耐性菌早期検出についての検討Oral presentation
- International Meeting on Emerging Diseases and Surveillance 2014, Nov. 2014, English, IMED, ウィーン, オーストリア, International conferenceCefmetazole for bactermia caused by ESBL-producting Enterobacteriacae comparing with carbapanemsPoster presentation
- 第65回日本皮膚科学会中部支部学術大会, Oct. 2014, Japanese, 日本皮膚科学会中部支部, 大阪, Domestic conference関節リウマチ患者に発症したMycobacterium chelonaeによる皮膚非結核性抗酸菌症の1例Oral presentation
- 第57回日本感染症学会中日本地方会学術集会, Oct. 2014, Japanese, 日本感染症学会, 岡山, Domestic conferenceカルバペネマーゼ産生腸内細菌(CPE)に対する各種検出試薬の検討Oral presentation
- 第54回日臨技近畿支部医学検査学会, Sep. 2014, Japanese, 日本臨床検査技師会近畿支部, 神戸, Domestic conferenceMALDI-TOFが有用であったMycobacterium fortuitum による左鼠系部皮下膿瘍の一症例Oral presentation
- 第88回日本感染症学会学術講演会, Jun. 2014, Japanese, The Japanese Association for Infectious Diseases, 福岡, Domestic conference腹腔静脈シャントバルブ留置中の肝硬変患者に結核性腹膜炎・喀痰塗抹検査陽性肺結核を認めた1例Oral presentation
- 第88回日本感染症学会学術講演会, Jun. 2014, Japanese, The Japanese Association for Infectious Diseases, 福岡, Domestic conference神戸大学医学部付属部病院におけるListeria monocytogenes 菌血症の背景因子Oral presentation
- 第62回日本化学療法学会総会, Jun. 2014, Japanese, 日本化学療法学会, 福岡, Domestic conference偽性腸閉塞症を伴うClostridium difficile感染症(CDI)の1例Poster presentation
- 第88回日本感染症学会学術講演会, Jun. 2014, English, The Japanese Association for Infectious Diseases, 福岡, Domestic conferenceIRIS of Kaposi sarcoma requiring systemic chemotherapy.Oral presentation
- 24th European Congress of Clinical Microbiology and Infectious Diseases( ECCMID ), May 2014, English, ESCMID, バルセロナ, スペイン, International conferenceDelay in diagnosis of infective endocarditis in JapanPoster presentation
- 第35回日本病院薬剤師会近畿学術大会, Feb. 2014, Japanese, 京都府病院薬剤師会日本病院薬剤師会近畿ブロック, 京都, Domestic conference未承認ワクチンの使用および保管管理体制の構築についてPoster presentation
- 第35回日本病院薬剤師会近畿学術大会, Feb. 2014, Japanese, 京都府病院薬剤師会日本病院薬剤師会近畿ブロック, 京都, Domestic conferenceAntimicrobial stewardshipの導入とその評価Oral presentation
- 第87回日本感染症学会学術講演会, Jun. 2013, Japanese, 日本感染症学会, 横浜, Domestic conferenceベンジルペニシリンカリウム療法における副作用発現に関する検討Poster presentation
- 第61回日本化学療法学会総会, Jun. 2013, Japanese, 横浜, Domestic conferenceベンジルペニシリンカリウム療法における副作用発現に関する検討Poster presentation
- 9th International Seminar on Disaster, Mar. 2013, English, Gajamada university/Kobe University, Yogyakarta, Indonesia, During the international disaster aid people have several risks. There are four kinds of risk such as morbidity, mortality, stress and premature attrition. Pre-departure assessment may be helpful to reduce such risks. There is another risk for disaster aid workers. In great east Japan earthquake not only aftershock or tsunami but nuclear plant explosion or chemicals were risks, International conferenceRisk for Disaseter Aid[Invited]Invited oral presentation
- 第34回日本病院薬剤師会近畿学術大会, Jan. 2013, Japanese, 日本病院薬剤師会, 滋賀, Domestic conferenceICUにおけるBig gunプロジェクト導入評価Poster presentation
- 第5回臨床リケッチア症研究会, Dec. 2012, Japanese, 日本臨床リケッチア症研究会, 滋賀, 症例は2-3年前からの時折の38度の発熱の42歳女性。受診2,3年前から時折38度を超える発熱があった。右手、右下腿の疼痛もあり、様々な医療機関を受診し、投薬されるも軽快せず、当院紹介受診された。その後、慢性疲労症候群と考え対症療法を行っていたところ、受診後14ヶ月の時点で左口角低下と左眼瞼下垂を認めた。片側性の末梢性顔面神経麻痺をきたしたことからライム病を考え、血清抗体を提出し、ドキシサイクリンを開始した。ドキシサイクリン100mg1日2回を開始するも吐き気にて内服不能となり3日後からアモキシシリン500mg1日3回に変更した。アモキシシリン投与開始後2日後から発熱と皮疹の出現を認め、Jarish-Herxheimer反応と考えた。その後、アモキシシリンを4週間投与し、治療を終了した。血清抗体ではIgM classではReact-Cti、P41,, Domestic conference慢性の発熱Oral presentation
- 第59回日本臨床検査医学会学術集会, Nov. 2012, Japanese, 日本臨床検査医学会, 京都, 神戸大学病院におけるESBL産生菌の分離状況の報告。, Domestic conference神戸大学病院におけるESBL産生菌の分離状況Oral presentation
- 第60回日本化学療法学会西日本支部総会, Nov. 2012, Japanese, 日本化学療法学会西日本支部, 福岡, 当院でのリネゾリドの使用許可制と使用状況の報告。, Domestic conferenceリネゾリドの使用許可制と使用状況についてOral presentation
- 第60回日本化学療法学会西日本支部総会, Nov. 2012, Japanese, 日本化学療法学会西日本支部, 福岡, 当院でのダプトマイシンの使用許可制と使用状況報告。, Domestic conferenceダプトマイシンの使用許可制と使用状況Oral presentation
- -, Oct. 2012, Japanese, The Japanese Association for Infectious Diseases, 福岡, 医療機関内におけるカルバペネム系抗菌薬の使用が増加するとその医療機関内部の緑膿菌のカルバペネム耐性株の増加を招く。このため、多くの日本の医療機関ではカルバペネム系抗菌薬の使用を届け出制にしたりし、必要以上の使用を制限している。神戸大学医学部付属病院では薬剤部が中心となり、微生物検査室、感染制御部、感染症内科が一体となったBig Gun projectと名付けた広域抗菌薬使用監視プログラムを行っている。具体的には緑膿菌用抗菌薬、抗MRSA薬を中心とした抗菌薬で「感染臓器」「病原微生物」を想定せずに乱用されている症例や無意味に予防投与として使用している症例などを中心に感染症内科へのコンサルトを進めたり、主治医に直接事情を聴取したりしている。 血液疾患における「好中球減少時の発熱」におけるempiric therapyの抗菌薬においてカルバペネムをどのよう, Domestic conference好中球減少時の抗菌薬投与~FNマネジメントと感染制御~[Invited]Nominated symposium
- 2012 Nordic Society of Clinical Microbiology and Infectious Diseases, Aug. 2012, English, Nordic Society of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, [Background] Bacillus cereus had been recognized as cause of nosocomial infections such as pneumonia, meningitis and catheter-related blood stream infection (CRBSI). Gram positive cocci, such as Staphylococcus aureus bacteremia (SAB) cause several complications such as persistent bacteremia, endocarditis and abscess. However, clinical manifestations and treatment of Bacillus ce, International conferenceClinical manifestation and complication of Bacillus cereus bacteremiaPoster presentation
- 第86回日本感染症学会年次総会, Apr. 2012, Japanese, The Japanese Association for Infectious Diseases, 長崎, Nocardia brasiliensisによるまれな感染症の報告, Domestic conference頻回の抗菌薬変更が必要となったNocardia brasiliensisによるリンパ管炎の一例Poster presentation
- 第86回日本感染症学会年次総会, Apr. 2012, Japanese, The Japanese Association for Infectious Diseases, 長崎, A群溶連菌以外のC群溶連菌、G群溶連菌による咽頭炎の報告, Domestic conference非A群溶連菌性連鎖球菌咽頭炎の2例Poster presentation
- 第86回日本感染症学会年次総会, Apr. 2012, Japanese, The Japanese Association for Infectious Diseases, 長崎, MSSAにおけるクリンダマイシン感受性の報告, Domestic conference当院でのMSSA及びMRSA菌血症におけるクリンダマイシンに対する感受性の相違、及び感受性の相違による予後の差の検討Poster presentation
- 第86回日本感染症学会年次総会, Apr. 2012, Japanese, The Japanese Association for Infectious Diseases, 長崎, 神戸大学附属病院においてはHIV感染症ではHBVの重複感染が80%程度に登, Domestic conference神戸大学附属病院におけるHIV患者における肝炎ウイルス重複感染の検討Poster presentation
- 第86回日本感染症学会年次総会, Apr. 2012, Japanese, The Japanese Association for Infectious Diseases, 長崎, Edwardsiella tardaによる壊死性筋膜炎の報告, Domestic conferenceNecrotizing fasciitis caused by Edwardsiella tardaPoster presentation
- The 8th I nternational Seminar"Humanitya nd SociaAl ctivity in DisasterS ituation", Mar. 2012, English, GADJAH MADA UNIVERSITY, ジョグジャカルタ, Indonesia, Domestic conferenceInfectious Disease after DisasterInvited oral presentation
- JDDW 2011, Oct. 2011, Japanese, 日本消化器病学会機構, 福岡, Domestic conference腸球菌性腹腔内感染症の疫学と臨床像Invited oral presentation
- 第21回日本医療薬学会年次総会, Oct. 2011, Japanese, 日本医療薬学会, 神戸, Domestic conference感染症診療における薬剤師の実践教育Invited oral presentation
- Infectious Diseases Society of America2011, Oct. 2011, English, Infectious Diseases Society of America, Boston, USA, International conferenceReduction of MRSA at a tertiary hospital in Japan since the introduction of a new infectious diseases departmentPoster presentation
- Scandinavian Society for Antimicrobial Chemotherapy, Aug. 2011, English, Scandinavian Society for Antimicrobial Chemotherapy, Reykjavik, Iceland, International conferenceClinical manifestations and complications of enterococcal bacteremiaPoster presentation
- 第85回日本感染症学会総会, Apr. 2011, Japanese, 日本感染症学会, 東京, Domestic conference院内発症Legionella pneumophila肺炎についてのDiversilabを用いた疫学的検討Poster presentation
- International Meeting on Emerging Diseases and Surveillance 2011, Feb. 2011, English, 国際感染症学会, Viena, オーストリア, International conferenceClinical manifestations and outcome in Bacillus cereus bacteremia "underestimated complications"Poster presentation
- 第32回日本病院薬剤師会近畿学術大会, Jan. 2011, Japanese, 日本病院薬剤師会, 神戸, Domestic conference抗菌薬管理体制(BIG GUNプロジェクト)の開始についてOral presentation
- 第58回化学療法学会総会, Jun. 2010, Japanese, 日本化学療法学会, 長崎, Domestic conferenceStreptococcus constellatusによる化膿性脊椎炎の一例Oral presentation
- 第84回日本感染症学会総会, Apr. 2010, Japanese, 日本感染症学会, 京都, Domestic conference術後の慢性Candida glabrata縦隔炎に対する長期治療の選択に苦慮した一例Poster presentation
- 第84回日本感染症学会総会, Apr. 2010, Japanese, 日本感染症学会, 京都, Domestic conferenceインフルエンザ迅速検査陽性にてタミフル処方された後、意識障害、右片麻痺、失語を来たした19歳女性Poster presentation
- 第84回日本感染症学会総会, Apr. 2010, Japanese, 日本感染症学会, 京都, Domestic conferenceSLEの長期経過中に亜急性の経過で皮下膿瘍をきたした1例Poster presentation
- 第84回日本感染症学会総会, Apr. 2010, Japanese, 日本感染症学会, 京都, Domestic conference1年の経過を経て再発したCandida tropicalisによる人工血管感染症Poster presentation
- 第77回日本感染症学会西日本地方会, Nov. 2008, Japanese, 日本感染症学会, 佐賀, Domestic conferenceGentamicin高度耐性Enterococcus faecalisの感染性心内膜炎の1例 アンピシリン、セフトリアキソン併用療法Oral presentation
- 第50回日本感染症学会中日本地方会, Oct. 2008, Japanese, 日本感染症学会, 神戸, Domestic conference血液培養からラセン菌が検出された!その正体は?Oral presentation
- 第82回日本感染症学会, Apr. 2008, Japanese, 日本感染症学会, 松江, Domestic conference猫よりの受傷歴の無い"Cat scratch disease(猫ひっかき病)"の1例Poster presentation
- 第82回日本感染症学会, Apr. 2008, Japanese, 日本感染症学会, 松江, Domestic conference東京都および千葉県の麻疹患者における検査室診断の結果についてPoster presentation
- 第82回日本感染症学会, Apr. 2008, Japanese, 日本感染症学会, 松江, Domestic conference進行する肝脾腫と腹水貯留にて受診した1例Poster presentation
- 第82回日本感染症学会, Apr. 2008, Japanese, 日本感染症学会, 松江, Domestic conference6ヵ月の経過で出現し、開胸肺生検にて診断された肺Mycobacterium szulgai感染症の1例Poster presentation
- 国立研究開発法人日本医療研究開発機構, 令和6年度 「デジタルヘルスケア開発・導入加速化事業」, Jul. 2025 - Mar. 2026細菌感染症菌種推定支援AI医療機器の経済効果に関する研究
- May 2023 - Mar. 2025, Principal investigator細菌の自動培養モニタリングシステムによる細菌有無判定精度評価
- Japan Agency for Medical Reserach and Development, 医療機器開発推進研究事業, Apr. 2021 - Mar. 2024, CoinvestigatorNonclinical reserach on identification of causative organisms and support system for antibiotic stewardship
- 国立研究開発法人科学技術振興機構, 未来社会創造事業, 未来社会創造事業, 神戸大学, Apr. 2020 - Mar. 2024, Coinvestigator社会リスク可視化システム、及び社会リスクに適切に対応する意思決定システムの開発
- 島津製作所, Nov. 2022 - Oct. 2023, CoinvestigatorEvaluation of AI guided bacterial species estimation system
- カーブジェン株式会社, Jul. 2022 - Dec. 2022, Coinvestigator not use grantsResearch and developement of automated gram staining machine
- 日本学術振興会, 科学研究費助成事業, 奨励研究, 神戸大学, 2019 - 2019梅毒患者を対象とした梅毒検査方法間の判定比較について梅毒は血清中の梅毒抗体を測定し診断している。血清学的検査法にはカルジオリピンを抗原とする方法(RPR)とトレポネーマ抗原を用いる方法(TP抗体)がある。また、これらの診断試薬は多数市販されているが、各診断試薬で反応性は異なりその程度は明らかにされていなかった。そのため、臨床診断を基準として、各診断薬の反応性を違いを比較研究するとRPR自動化定量法のメーカー間差は少なかったが生物学的偽陽性はいずれの方法においても確認できた。FTA-ABSは感度が悪く、TP抗体は定量法が望ましく、定量値は治療後モニタリングに使用できる可能性があった。
- Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists (B), Kobe University, 01 Apr. 2012 - 31 Mar. 2016, Principal investigatorWe investigated the difference between voluntary disaster aid and occupational disaster aid. We took survey for college students in Hyogo, Miyagi, Iwate, Aomori and Fukushima prefectures.Among 62 colleges, 38 college had the division which manage safety and health of voluntary aid college students. 17 college answered about support system about voluntary aid students and 4 colleges assessed the risk of disaster aid. However, no college performed appropriate risk assessment and management on disaster aid. It would be feasible for voluntary disaster aids to consult an occupational safety and health expert before the mission.Competitive research funding